0001662252-23-000007.txt : 20230113 0001662252-23-000007.hdr.sgml : 20230113 20230113143654 ACCESSION NUMBER: 0001662252-23-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regenicin, Inc. CENTRAL INDEX KEY: 0001412659 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: WY FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-146834 FILM NUMBER: 23528408 BUSINESS ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: (973) 557-8914 MAIL ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: Windstar Inc. DATE OF NAME CHANGE: 20070918 10-K 1 rgin10k.htm 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended September 30, 2022

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
	For the period from to __________

	Commission File Number: 333-146834

Regenicin, Inc.

(Exact name of registrant as specified in its charter)

Wyoming	27-3083341
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

10 High Court, Little Falls, NJ	07424
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number: 973 557 8914

Securities registered under Section 12(b) of the Exchange Act
Title of each class	Name of each exchange on which registered
None	not applicable

Securities registered under Section 12(g) of the Exchange Act:
Title of each class
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☐Yes ☒ No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Non-accelerated Filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes ☒No

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed fiscal quarter: Approximately $1,534,830 as of December 31, 2022.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 153,483,050 as of December 31, 2022.

NOTICE: THIS 10K FILING DOES NOT CONTAIN FINANCIAL OR OTHER INFORMATION WHICH HAS BEEN AUDITED OR REVIEWED BY OUR INDEPENDENT PUBLIC ACCOUNTING FIRM FOR REASONS SPECIFIED HEREIN. WE INTEND TO SUPPLEMENT THIS FILING, AT A CURRENTLY UNKNOWN LATER DATE, WITH SUCH AUDITED FINANCIAL INFORMATION, IF AND WHEN SUCH AN AUDIT CAN BE OBTAINED.

Table of Contents

TABLE OF CONTENTS

		Page
PART I
Item 1.	Business	3
Item 1A.	Risk Factors	5
Item 1B.	Unresolved Staff Comments	6
Item 2.	Properties	6
Item 3.	Legal Proceedings	6
Item 4.	Mine Safety Disclosures	6
PART II
Item 5.	Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6.	Selected Financial Data	9
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	11
Item 8.	Financial Statements and Supplementary Data	11
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	12
Item 9A.	Controls and Procedures	12
Item 9B.	Other Information	13
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	14
Item 11.	Executive Compensation	16
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	17
Item 13.	Certain Relationships and Related Transactions, and Director Independence	18
Item 14.	Principal Accountant Fees and Services	18
	PART IV
Item 15.	Exhibits, Financial Statement Schedules	19

Table of Contents

PART I

Item 1. Business

Overview of key events of the year ended September 30, 2022

During 2021-22, we continued to work on obtaining funding in order to start clinical trials and gain FDA product approval for our product, NovaDerm^®. Having secured an Orphan Drug Designation as a biologic for this product, we continued to comply with the FDA annual reporting requirements.

To avoid the introduction of pathogens when using materials from animals to produce drugs, devices, and biologics, NovaDerm^® and future Regenicin products all use tracible and pure animal sourced materials. We have worked with the FDA to ensure we are meeting federal expectations in this regard during the production process.

We estimate that the completion of the IND and the clinical trials will take at least 18 months and cost in excess of $7 million. In addition to the completion of the IND, the only other significant gating item to enter clinical trials has been finding funding for this process.

Subsequent to the end of this fiscal year, we began selling materials and rights to our NovaDerm^® product to individuals through a new Nevada series LLC we set up, NovaDerm Product Package LLC, as more fully described in the next section entitled ‘Our Business Moving Forward In 2023’. These rights and material sales generated a substantial amount of funding which we believe will provide us enough capital to complete the NovaDerm IND and allow us to proceed with the Clinical Trials of our NovaDerm^® product. No assurance can be given, however, as to the results of such Clinical Trials, any future FDA approval, or our ability to complete and offer our NovaDerm^® product commercially in the future.

Three board positions remain open on our Board of Directors.

Importantly, we are filing this annual report without our auditor’s review or any audit of our financial information or this report. Our reason for doing this is that we are still negotiating with our potential auditors for the completion of an audit and review of our unaudited past years reports prior to obtaining an audit of this current 10K filing. Instead, we have provided herein information as typically presented in our 10K annual report, including financial information, which has not been reviewed or audited by any independent outside source.

We intend, if and when able, to file an amendment to this 10K filing with such audited information. We are unaware at this time when we will obtain the necessary audit of the current and past filings; however, we will continue to provide current information to investors and the public when we are able through either our EDGAR filings and/or through postings on our website.

Our Business Moving Forward In 2023

Subsequent to the end of this fiscal year, in October 2022, we set up a new Nevada Series LLC called NovaDerm Product Package, LLC (“NPP LLC”). During November and December 2022, consistent with Nevada law governing this Master Series LLC, we then establish twenty-five (25) individual series LLCs, identifying each with a series letter of A through T or AA through EE. Thus, each of these sub-entities were named NovaDerm Product Package Series A, LLC through Series T, LLC, and then Series AA to Series EE, LLC (or NPP-A through NPP-T and NPP-AA through NPP-EE for short).

Into each of these twenty-five individual Series LLCs, we contributed the right and exclusive ownership to a certain amount of the bovine hides and corium we currently own and use as key materials in the preparation of our NovaDerm® product, as well as the right to designate: (a) the specific patient cultured skin to be prepared from these materials; (b) the amount of this cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC we designated 33,333 cm² of these NovaDerm® Product Rights. For NPP-DD we designated 30,625 cm² of NovaDerm® Product Rights and for NPP-EE we designated 28,783 cm² of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued.

While we retain possession of the materials transferred in each Series LLC contribution, we have a continuing obligation to segregated and manage those materials as well as to prepare the NovaDerm® cultured skin product as designated by each Series LLC holder or their designate. The identified materials are currently set apart from other such materials and are being held by us pending the identification of the patient and medical facility as instructed by each NovaDerm® Product Rights holder. Notwithstanding this retention of possession by us, the ownership and legal title to the materials are retained and fully vested in the individual Series LLC or its designate.

Table of Contents

The above-described transfers of membership interests in the Series LLCs generated a substantial amount of cash which we are obligated to use for the completion of our NovaDerm IND and the administration of our product clinical trials. No assurance, however, can be given as to the success or failure of such IND or clinical trials, or as to any future FDA decisions made following these trials.

Our major objective for 2023 remains to complete the requirements of our NovaDerm IND application and begin our clinical trials. It is estimated that the cost to finalize the IND will be approximately $1.9 million dollars, and the cost to complete Phase 1/2 of the clinical trial will be approximately 5.0 million dollars. There can be no assurance that we will be able to complete these tasks for these estimated amounts or that we will be successful in the proving out our NovaDerm® Product in this process. Indeed, clinic trials are notoriously difficult and expensive and are likely to result in additional unplanned costs and a denial of FDA approval.

As previously reported, our goal in obtaining funding for this process has been to minimize shareholders' dilution as much as possible. We believe the manner in which we structured our sales of NovaDerm® Product Rights has successfully achieved this objective. We will continue to work with potential investors in order to pursue other necessary funding based on our stated objective of successfully completing our planned clinical trials and obtaining FDA approval for the commercial sale of our NovaDerm® Product. It has taken longer to raise the funds than originally estimated; however, we remain hopeful that our goal is now achievable.

In the preparation of the IND application, we will continue to develop the testing suggested by the FDA during our Pre-IND meeting. Our scaffold supplier continues to perform the FDA suggested testing on collagen processing which addresses Bovine Closed Herd requirements for the enhanced safety and traceability of the collagen scaffolds used to produce NovaDerm^®. We will be entering into discussions and evaluation of possible clinical trial sites for NovaDerm^® as we proceed through the FDA approval process. Our discussions so far have confirmed that patient recruitment and enrollment should be faster and less complicated than other clinical trials because of our Orphan Designation and the fact that the surgical protocol will be similar to the grafting procedures currently in use at most facilities. NovaDerm^® should thus require minimal physician training and documentation to complete the clinical trial, when and if conducted.

We are in the process of preparing a detailed plan and timeline for the filing of our IND and commencement of clinical trials and will provide this information when complete and approved by our board of directors. Our initial trials are planned to begin with a total of ten subjects and an Initial Data Safety Monitoring Board, (DSMB), review of safety on the first three subjects once they have reached 6 months follow-up. We do not intend to interrupt our trial waiting for the DSMB report. Our management’s approach is to set up the trials so as to allow for a seamless transition into commercial production upon approval. We have arranged for sufficient Bovine Closed Herd corium to produce sufficient collagen scaffolds to meet our needs for the clinical trials once the IND is approved.

Our First Product Candidate NovaDerm^®

Our first cultured skin substitute product candidate, NovaDerm^®, is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient’s own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. Clinically, we expect our Cultured Skin substitute self-to-self skin graft product will perform the same as split thickness allograft skin. Our Autologous cultured skin substitute should not be rejected by the immune system of the patient, unlike porcine or cadaver cellular grafts. Immune system rejection is a serious concern in Xeno-transplant procedures which have a cellular component. The use of our cultured skin substitute should not require any specialized physician training because it is applied the same as in a standard split thickness allograft procedure.

NovaDerm^®does not require the large harvest areas that are required when performing split thickness allograft procedures. NovaDerm^®is designed to need only a small area of harvest material to cover the wound. This is a marked improvement over split thickness allograft skin which can be stretched only 2 to 4 times its original coverage area. This results in limitations on how much burned area can be covered with this procedure. When a patient has more than 50% of their body with full thickness burns, there is simply not enough harvest area available to cover the burned area. As a result, the same area harvested must be allowed to grow back to get enough replacement skin, allowing for a high risk of infection and even mortality. NovaDerm^® is expected to expand 100 to 400 times in coverage, greatly reducing this problem as well as scarring caused by harvesting.

Clinically speaking, a product designed to treat a life-threatening condition must be available for the patient when needed. Our Culture skin substitute is being developed to be ready to apply to the patient within the first month of admission to the hospital, when the patient is ready for grafting. Patients with serious burn injuries may not be in a condition to be grafted on a predefined schedule made more than a month in advance. Therefore, in order to accommodate the patient’s needs, we are striving to ensure that our cultured skin substitute will have an adequate shelf life and manufacturing schedule to ensure it is available whether the patient needs it the first month, or any day after, until the patient’s wound is completely covered and closed. We intend to provide a patient with enough NovaDerm^® to meet the patients’ needs in a single lot of material with adequate shelf life to be available when the patient is ready. With an extended shelf life and enough material in the first shipment, a physician may perform a second grafting 5 to 10 days post the first grafting period.

At this time, we first plan to seek FDA approval for burns as an Orphan Biologic Product to establish significant safety data and then seek Biological License Approval.

Our second product is anticipated to be TempaDerm® . TempaDerm® uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients, such as ulcers. This product is expected to have applications in the treatment of chronic skin wounds such as diabetic ulcers, decubitus ulcers and venous stasis ulcers. This product is expected to be similar to our burn indication product, except for the indications, and it will not depend totally on autologous cells. In fact, it may be possible to use the excess cultured skin that was originally produced for use on the patient that donated the cells to grow the skin. Potentially, TempaDerm^® will be able to take this original cultured skin and use it on someone other than the original donor.

As currently planned, TempaDerm^® has the possibility of using banked cells, or even frozen cultured skin substitutes, to carry inventory to satisfy unknown needs or large volumes to meet the demands created in large scale disasters. Because of our focus to date on NovaDerm^®, we have taken only limited steps toward the development of TempaDerm^®. We may also decellularize TempaDerm^® or NovaDerm^® to make collagen wound coverings containing all the natural growth promoters found in skin.

We believe this technology has many different uses beyond the burn indication. The other uses may include chronic wounds, reconstructive surgery, and potentially other complex organs and tissues. Some of the individual components of our planned cultured skin substitute technology is expected to be developed for devices, such as tendon wraps made of collagen or collagen temporary coverings of large area wounds to protect the patients from infections while waiting for a permanent skin substitute. The collagen technology used for cultured skin substitutes, as designed, is expected to be used for many different applications in wound healing and stem cell technology and even drug delivery systems.

Table of Contents

Competition

Several companies have developed or are developing products that propose to approach the markets described above. There is only one other Autologous Cultured Skin Substitute for severe burns designated as an orphan product candidate, the original Cutanogen’s PermaDerm. This product was licensed by Amarantus to Emerald Organic Products, but, to our knowledge, it has not be approved by the FDA or gone through any clinical trials .

In any case, we believe our product is superior in design and function and, thus, provides significant advantages over this competitor. The advantages of our cultured skin substitute include: (a) simultaneous delivery of autologous epidermal keratinocytes and fibroblasts organized with a unique collagen base, (b) it can be produced and ready for patient use in 21 to 28 days, and (c) it has a shelf life of up to 2 weeks once produced.

Government Regulation

The Pediatric Medical Device Safety and Improvement Act of 2007 (Public Law 110-85) provides that Orphan Product applications for pediatric use only, or for use in both pediatric and adult patients, that are approved on or after September 27, 2007, are assigned an annual distribution number (ADN) and may be sold for profit (subject to the upper limit of the ADN). In addition, once a product receives an Orphan BLA, the developer of the product receives up to seven years market exclusivity for a specific indication following the product’s approval by the FDA.

Unrestricted sales of our cultured skin substitute will not be permitted until we have obtained full FDA approval after data for safety and efficacy are collected from an approved clinical study. Once an IND is submitted, we expect enrollment and treatment to require a full one-year of evaluation on each patient before our product can be fully assessed for human use. The final 3 months of the evaluation is expected to be only a monitoring period. After collection of data from the clinical trial and submission to the FDA, six months is typically planned for the FDA’s review and comments before a decision will be reached on whether or not to approve our product and what limitations on its use may be placed. Because of our Orphan Designation, this review time is expected to be reduced significantly.

Intellectual Property

In 2016, we received a registered trademark for NovaDerm^®.

Employees

As of September 30, 2022, we had 3 employees.

Subsidiaries

In September, 2013, Regenicin formed a wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia. This subsidiary has been inactive since its formation.

On August 31, 2022, we filed articles of continuance with the states of Nevada and Wyoming effectively moving our organizational jurisdiction from Nevada to Wyoming effective on that date.

Item 1A. Risk Factors.

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 1B. Unresolved Staff Comments.

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Properties

Our principal executive offices are located at 10 High Court, Little Falls, NJ 07424. Our headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Randall McCoy, our Chief Executive Officer. The office is attached to his residence but has its own entrances, rest room and kitchen facilities. No rent is charged.

We also maintain an office at 3 Arvida Drive, Pennington NJ 08534, which is an FDA registered, cGMP compliant FDA audited facility. This office is owned by Materials Testing Laboratory, and the principal is an officer of our company. No rent is charged.

Item 3. Legal Proceedings

On September 30, 2013, we filed a lawsuit against Lonza Walkersville and others in Fulton County Superior Court in the State of Georgia.

Other than as mentioned above, we have no threatened or pending litigation.

Item 4. Mine Safety Disclosures

N/A

Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock was previously quoted under the symbol “RGIN” on the OTCBB operated by the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the OTCQB operated by OTC Markets Group, Inc. Few market makers continue to participate in the OTCBB system because of high fees charged by FINRA and we are not quoted at all because of our failure in the past few years to provide audited financial information. Consequently, market makers that once quoted our shares on the OTCBB system no longer are posting any quotation and trades are not generally available on this or other market reporting services.

Only a limited market exists for the purchase and sale of our securities. There is no assurance that a regular trading market will ever develop again, or if developed, that it will be sustained. Therefore, a shareholder may be unable to resell his securities in our company. Moreover, as a result of the limited trading and information on the pricing of our stock we are unable to provide a table showing a range of high and low bid quotations for our common stock during recent periods and we believe that any such information would be misleading because of the difficulty in determining these quotations.

Penny Stock

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.

These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have additional difficulty selling our securities.

Table of Contents

Holders of Our Common Stock

As of December 31, 2022, we had 153,483,050 shares of our common stock issued and outstanding, held by 112 shareholders of record, with others holding shares in street name.

Dividends

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:

1. we would not be able to pay our debts as they become due in the usual course of business, or;

2. our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

Recent Sales of Unregistered Securities

For the fiscal years ended September 30, 2022 and September 30, 2021, we did not issue common stock.

Shares and Warrants to be issued:

No warrants were issued in fiscal years ended September 2021 or 2022.

Securities Authorized for Issuance under Equity Compensation Plans

The following table provides information about our compensation plans under which shares of common stock may be issued upon the exercise of options as of September 30, 2022.

Plan Category	Number of securities to be issued upon exercise of outstanding option, warrants and rights		Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuances under equity compensation plans
Equity compensation plans approved by security holders		0		0		0
Equity compensation plans not approved by security holders		11,771,344	$	0.02		0
Total		11,771,344	$	0.02		0

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to our employees, officers, directors and consultants, including incentive stock options, non-qualified stock options, restricted stock, and other benefits. The Plan provides for the issuance of up to 3,542,688 shares of our common stock.

On January 6, 2011, we approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price is $0.62 per share. The options vested over a three-year period and expire on December 22, 2015. On May 11, 2011, the terms of the options were amended to allow for immediate vesting. On December 10, 2013, we approved the amendment to those options to change the exercise price to $0.035 per share. On December 22, 2015 the Board extended the term of the options to December 31, 2021, and then extended the term of these options again with regard to its current active board members until December 31, 2023.

In addition, on January 15, 2015, the company entered into a stock option agreement with an officer of the company. The agreement grants the officer an option to purchase 10 million shares of common stock at $0.02 per share, and was to expire January 15, 2021. This option grant was extended by action of the Board of Directors until December 31, 2023.

Table of Contents

Warrants Issued and Outstanding

No warrants were outstanding at September 30, 2022.

Item 6. Selected Financial Data

A smaller reporting company is not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

See discussion in section marked: ‘Our Business Moving Forward In 2023’

Results of Operations for the Fiscal Years Ended September 30, 2022 and 2021

We generated no revenues from September 6, 2007 (date of inception) to September 30, 2022.

We incurred operating expenses of $601,179 for the year ended September 30, 2022, compared with operating expenses of $635,864 for the year ended September 30, 2021. Our operating expenses decreased in 2022 from 2021, and are compared as follows:

Operating Expenses	September 30, 2022		September 30, 2021
General and Administrative	$	635,864	$	663,749
Stock Based Compensation	$	38,083	$	34,738

We incurred net other expense of $38,083 for the year ended September 30, 2022, as compared to net other expense of $34,738 for the year ended September 30, 2021. Our other income and expenses for 2022 consisted of interest expenses of $36,258 and a loss on other than temporary decline in the fair value of Amarantus stock of $1,825. Our other income and expenses for 2021 consisted of interest expenses of $34,713 and a loss on other than temporary decline in the fair value of Amarantus stock of $25.

We had a net loss of $639,262 for the year ended September 30, 2022, as compared with a loss of $670,602 for the prior year. The decrease in loss was due to the reversal of accounts payable in the year ended September 30, 2022 of $31,340, which decreased the loss.

Our net loss attributable to common stockholders for the year ended September 30, 2022 was $692,216 compared to a net loss of $741,007 for the year ended September 30, 2021. The decrease in loss was due to the reversal of accounts payable in the year ended September 30, 2022 of $48,791.

Table of Contents

Liquidity and Capital Resources

As of September 30, 2022, we had cash of $14,568 and investments of $925, for total current assets of $15,493. Our total current liabilities as of September 30, 2021 were $5,612,633. We had a working capital deficit of $5,597,140 as of September 30, 2022.

Operating activities used a net $27,291 in cash for the year ended September 30, 2022. Financing activities provided $40,000 for the year ended September 30, 2022 and consisted entirely of proceeds from loans from officers.

We have issued various promissory notes over the course of the last several fiscal years in order to continue funding our operations. The terms of these promissory notes are detailed in Note F to the financial statements accompanying this Annual Report. While this financing has been helpful in the short term to meet our financial obligations, we have been seeking other types of financing to fund our operations over the coming year.

Going Concern

Our financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred cumulative losses to date, expect to incur further losses in the development of our business, and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Accordingly, this is the policy we believe is the most critical to aid in fully understanding and evaluating our financial condition and results of operations.

1. Income Taxes - The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, " Income Taxes ," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. The Company has adopted the provisions of FASB ASC 740-10-05 " Accounting for Uncertainty in Income Taxes ." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

Development Stage Activities and Operations

The Company is in the development stage and has had no revenues for the current reported year. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.

Table of Contents

Recently Issued Accounting Pronouncements

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the condensed financial statements of the Company.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 8. Financial Statements and Supplementary Data

Index to Financial Statements Required by Article 8 of Regulation S-X:

UNAUDITED Financial Statements:
F-1	Consolidated Balance Sheets as of September 30, 2022 and 2021
F-2	Consolidated Statements of Operations for the years ended September 30, 2022 and September 30, 2021
F-3	Consolidated Statement of Stockholders’ Deficiency for the years ended September 30, 2022 and September 30, 2021
F-4	Consolidated Statements of Cash Flows for the years ended September 30, 2022 and September 30, 2021
F-5	Notes to Consolidated Financial Statements

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2022			September 30, 2021
ASSETS
CURRENT ASSETS
Cash	$	14,569		$	1,859
Common stock of Amarantus		925			2,750
Total current and total assets	$	15,493		$	4,609
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable	$	103,119		$	93,674
Accrued expenses - other (related party of $65,471 and $46,713)		254,595			234,894
Accrued salaries - officers		4,612,001			4,031,001
Promissory note payable		175,000			175,000
Convertible promissory note - officer		335,683			335,683
Loan payable		10,000			10,000
Loans payable - officer		122,235			82,235
Total current and total liabilities		5,612,633			4,962,487
STOCKHOLDERS' DEFICIENCY
Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding		885			885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding		157,914			157,914
Additional paid-in capital		10,208,339			10,208,339
Accumulated deficit		(15,959,850	)		(15,320,588	)
Less: treasury stock; 4,428,360 shares at par		(4,428	)		(4,428	)
Total stockholders' deficiency		(5,597,140	)		(4,957,878	)
Total liabilities and stockholders' deficiency	$	15,493		$	4,609

See Notes to Consolidated Financial Statements.

F-1

Table of Contents

REGENICIN, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Year Ended September 30, 2022			Year Ended September 30, 2021
Revenues	$	—		$	—
Operating expenses
General and administrative		601,179			635,864
Total operating expenses		601,179			635,864
Operating loss before other expenses		(601,179	)		(635,864	)
Other expenses
Interest expense related party of $(18,758), $(17,213)		(36,258	)		(34,713	)
Change in unrealized loss on securities		(1,825	)		(25	)
Total other expenses		(38,083	)		(34,738	)
Net loss		(639,262	)		(670,602	)
Preferred stock dividends		(52,954	)		(70,405	)
Net loss attributable to common stockholders	$	(692,216	)	$	(741,007	)
Loss per share basic	$	(0.00	)	$	(0.00	)
Loss per share diluted	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding basic		153,483,050			153,483,050
Weighted average number of shares outstanding diluted		153,483,050			153,483,050

See Notes to Consolidated Financial Statements.

F-2

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY

(UNAUDITED)


					Additional
	Convertible Preferred Stock		Common Stock		Paid-in	Accumulated	Treasury
	Shares	Amount	Shares	Amount	Capital	Deficit	Stock (1)	Total

Balances at October 1, 2021	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,320,588)	$ (4,428)	(4,957,878)
Net loss	—	—	—	—	—	(639,262)	—	(639,262)
Balances at September 30, 2022	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,959,850)	$ (4,428)	$ (5,597,140)
Balances at October 1, 2020	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (14,649,986)	$ (4,428)	(4,287,276)
Net loss	—	—	—	—	—	(670,602)	—	(670,602)
Balances at September 30, 2021	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,320,588)	$ (4,428)	$ (4,957,878)

(1) The number of shares in treasury stock for all periods presented was 4,428,360.

See Notes to Consolidated Financial Statements.

F-3

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

		Year Ended September 30, 2022			Year Ended September 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(639,262	)	$	(670,602	)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investment		1,825			25
Accrued interest on loans and notes payable		36,258			34,713
Changes in operating assets and liabilities
Accounts payable		9,443			5,015
Accrued expenses - other		(16,555	)		25,743
Accrued salaries - officers		581,000			580,999
Net cash used in operating activities		(27,291	)		(24,107	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds of loans from officers		40,000			24,600
Net cash provided by financing activities		40,000			24,600
NET INCREASE IN CASH		12,709			493
CASH - BEGINNING OF PERIOD		1,859			1,366
CASH - END OF PERIOD	$	14,568		$	1,859
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—

See Notes to Consolidated Financial Statements.

F-4

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A - THE COMPANY

Regenicin, Inc. ("Regenicin"), formerly known as Windstar, Inc., was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. On August 31, 2022, we filed articles of continuance with the states of Nevada and Wyoming effectively moving our organizational jurisdiction from Nevada to Wyoming effective on that date. The Company's business plan is to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation:

The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated.

Going Concern:

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of September 30, 2022, has an accumulated deficit of approximately $15.95 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Income (loss) per share:

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares:

	2022				2021
Options		—				—

The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net losses incurred during 2022 and 2021:

	2022		2021
Options		11,771,344		11,771,344
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		35,712,910		16,784,150
Shares excluded from the calculation of diluted loss per share		56,334,254		37,405,494

F-5

Table of Contents

Financial Instruments and Fair Value Measurement:

As of October 1, 2018, the Company adopted ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There no longer is an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. As a result of the adoption, the Company recorded a cumulative effect adjustment of a $950 decrease to accumulated other comprehensive income, and a corresponding decrease to accumulated deficit, as of October 1, 2018.

Common stock of Amarantus BioScience Holdings, Inc. ("Amarantus") is carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, and unrealized gains and losses are included in other income (expense) on the statement of operations.

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at September 30, 2022 is $925. The change in unrealized loss for the year ended September 30, 2022 and 2021 was $1,825 and $25 net of income taxes, respectively, and was reported as other expense.

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of and September 30, 2022 and 2021 due to their short-term nature.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimation includes the selection of assumptions underlying the calculation of the fair value of options. Actual results could differ from those estimates.

Stock-Based Compensation:

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option pricing model.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505.

F-6

Table of Contents

Income Taxes:

The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, "Income Taxes," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.

The Company has adopted the provisions of FASB ASC 740-10-05 "Accounting for Uncertainty in Income Taxes." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

Recently Issued Accounting Pronouncements:

NOTE C – LICENSE OF RIGHTS

On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus BioScience Holdings, Inc. (“Amarantus”). Under the Sale Agreement, the Company granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus could exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. The option had not been exercised and had since expired.

NOTE D – ACCRUED EXPENSES

Accrued expenses consisted of the following:

	2022		2021
Professional fees	$	9,186	$	25,743
Interest		245,409		209,151
Accrued expenses	$	254,595	$	234,894

F-7

Table of Contents

NOTE E - LOANS PAYABLE

Convertible Promissory Note - Officer:

Through March 31, 2020, John Weber, the Company's Chief Financial Officer, advanced the Company a total of $335,683. On March 31, 2020, these advances were converted into a convertible promissory note. Interest on the note is computed at 5% per annum and accrues from the time of the advances until the maturity date. The original maturity date was September 30, 2020, at which time all the accrued interest and principal became due. The note has been extended several times and most recently to September 30, 2022. For the years ended September 30, 2022 and 2021 interest totaling $18,758 and $17,213 respectively was incurred and accrued. Lifetime accrued interest on the note was $65,471 and $46,713 at September 30, 2022 and 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets The note is convertible at the option of Mr. Weber into shares of the Company's common stock at the prevailing market rate on the date of conversion.

Loan Payable:

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both September 30, 2022 and 2021, the loan payable totaled $10,000.

Loans Payable - Officer:

Through September 30, 2019, J. Roy Nelson, the Company's Chief Science Officer, made net advances to the Company totaling $26,935. The loans do not bear interest and are due on demand.

In September 2018, Randall McCoy, the Company's Chief Executive Officer, advanced to the Company $4,500. The loan does not bear interest and is due on demand.

From July 2020 to September 2022, John Weber, the Company’s Chief Financial Officer, advanced to the Company a total of $90,800. The bears interest at 5% per annum and is due on demand.

NOTE F – PROMISSORY NOTES PAYABLE

Bridge Financing:

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both September 30, 2022 and 2021, the note balance was $175,000. Interest expense was $17,500 for each of the years ended September 30, 2022, and 2021, respectively. Accrued interest on the note was $179,938 and $162,438 at September 30, 2022 and 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets.

NOTE G - RELATED PARTY TRANSACTIONS

The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An officer of the Company is an owner of CPR. No rent is charged for either premise.

On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

See NoteE for loans payable to related parties.

F-8

Table of Contents

NOTE H - INCOME TAXES

The Company did not incur current income tax expense for either of the years ended September 30, 2022 or 2021.

At September 30, 2022, the Company had available approximately $4.6 million of net operating loss (“NOL”) carry forwards which expire in the years 2029 through 2037. However, the use of the net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code. The Company has not yet undertaken the process to calculate these changes.

Significant components of the Company’s deferred tax assets at September 30, 2022 and 2021 are as follows:

	2022			2021
Net operating loss carry forwards	$	1,235,018		$	1,229,570
Unrealized loss		808,940			807,975
Stock based compensation		17,061			17,061
Accrued expenses		1,247,940			1,091,070
Total deferred tax assets		3,308,959			3,145,676
Valuation allowance		(3,308,959	)		(3,145,676	)
Net deferred tax assets	$	—		$	—

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

The following is a reconciliation of the Company’s income tax rate using the federal statutory rate to the actual income tax rate as of September 30, 2022 and 2021:

	2022			2021
Federal tax rate		(21	)%		(21	)%
Effect of state taxes		(6	)%		(6	)%
Effect of NOL		(2	)%		(2	)%
Change in valuation allowance		25	%		25	%
Total		0	%		0	%

At September 30, 2022 and 2021, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of September 30, 2022, and 2021 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

The Company files its federal and state income tax returns under a statute of limitations. The tax years ended September 30, 2020 through September 30, 2022 generally remain subject to examination by federal tax authorities.

F-9

Table of Contents

NOTE I - STOCKHOLDERS’ DEFICIENCY

Preferred Stock:

Series A

Series A Preferred earns a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of September 30, 2022 and 2021 plus dividends in arrears as per below). Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three-year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. There have been no new developments related to the remaining Series A holders regarding this claim and the conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit.

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of September 30, 2022, and 2021, dividends in arrears were $818,030 ($.92 per share) and $747,232 ($.84 per share), respectively.

At both September 30, 2022 and 2021, 885,000 shares of Series A Preferred were outstanding.

Series B

On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). 4,000,000 shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Preferred have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At September 30, 2021, and 2020 no shares of Series B Preferred are outstanding.

2010 Incentive Plan:

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to the Company’s employees, officers, directors and consultants. The Plan provides for the issuance of up to 4,428,360 shares of the Company’s common stock.

Effective October 1, 2019, the Company adopted ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The adoption of ASU 2018-07 did not have a significant impact on the Company’s consolidated financial statements.

On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire, as extended, on December 31, 2018. Effective as of the expiration date, the Company extended the term of those options for two of the directors to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company's shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $1,316 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.035, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years.

On January 15, 2015, the Company approved the issuance of 10,000,000 options to one of its Officers at an exercise price of $0.02, per share that were set to expire on January 15, 2019. Effective December 31, 2019, the Company extended the term of those options to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $29,508 in compensation expense, which is included in the results of operations for the year ended September 30, 2021. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.02, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years

Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company’s common stock as the Company’s common stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.

No stock based compensation was recorded the years ended September 30, 2022 and 2021.

F-10

Table of Contents

Option activity for 2022 and 2020 is summarized as follows:

	Options		Weighted Average Exercise Price
Options outstanding, October 1, 2020		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2021		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2022		11,771,334	$	0.019
Aggregate intrinsic value	$	0

The aggregate intrinsic value was calculated based on the positive difference between the closing market price of the Company’s Common Stock and the exercise price of the underlying options.

The following table summarizes information regarding stock options outstanding at September 30, 2022:

				Weighted Average Remaining				Options Exercisable Weighted Average
Ranges of prices		Number Outstanding		Contractual Life		Exercise Price		Number Exercisable		Exercise Price
$	0.020		10,000,000		1.25	$	0.020		10,000,000	$	0.020
$	0.035		1,771,344		1.25	$	0.035		1,771,344	$	0.035
	$0.020-$0.035		11,771,334		1.25	$	0.019		11,771,344	$	0.022

As of September 30, 2022, there was no unrecognized compensation cost related to non-vested options granted.

NOTE J - SUBSEQUENT EVENTS

We subsequently transferred 99% of our membership interests (or 99 membership interests) in each of these Series LLC to various Limited Liability Companies, held by individuals unknown to us, in exchange for a pre-agreed payment. Prior to year-end, the members of these LLCs voted to donate 100% of the membership interests to charity.

F-11

Table of Contents

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

No events occurred requiring disclosure under Item 304 of Regulation S-K during the fiscal year ending September 30, 2022.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this annual report, being September 30, 2022. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this annual report.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of September 30, 2022 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of September 30, 2022, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending September 30, 2022, depending on available funds: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to an exemption for non-accelerated filers set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Table of Contents

Remediation of Material Weakness

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we receive financing to hire additional employees.

Limitations on the Effectiveness of Internal Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

Item 9B. Other Information

None

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following table contains information with respect to our current executive officers and directors:

Name	Age		Principal Positions With Us
Randall McCoy		72	Chief Executive Officer and Director
John J. Weber		72	Chief Financial Officer and Director
Dr. J. Roy Nelson		73	Chief Science Officer

Randall McCoy has served as our Chief Executive Officer and director since July 2010. Prior to joining the Company, Mr. McCoy served as President of McCoy Enterprises LLC since its founding in May 2002. Mr. McCoy has more than 43 years of experience in the healthcare industry and has assisted both small and major pharmaceutical/device companies address FDA issues. He served as Laboratory Manager and Instructor at both George Washington University and Temple Medical School, and served as Program Manager at the Stanford Research Institute, Healthcare Division, of the David Sarnoff Research Center. Mr. McCoy has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and world market. He currently holds over 30 US and international patents.

John J. Weber has served as our Chief Financial Officer and Director since September 13, 2010. Mr. Weber served as the Executive Vice President of Fujifilm Medical Systems, USA from 2006 until 2009. While at Fujifilm he was responsible for overseeing all corporate activity with the exception of R&D. In previous positions at Fujifilm he served as Senior Vice President of Operations as well as Chief Financial Officer.

Mr. Weber brings over 20 years of medical-related corporate, operational and financial management experience to the Company.

Dr. J. Roy Nelson Chief Science Officer owns and operates a FDA registered cGMP audited laboratory. The Material Testing Laboratory holds a Schedule I-V DEA drug license and with an electronic FDA submission portal. His laboratory provides material science supports for new medical devices and drug support for major pharmaceutical as well as smaller companies. In addition to numerous medical device and drug developmental projects, he has been on two FDA consent decree remediations writing SOPs and other FDA compliance documents. He has eight years experience working with various collagen products, such as sponges. Prior to 1988 Dr. Nelson was a senior material scientist at RCA/SRI in Princeton, NJ. He has more than twenty US patents. Dr. Nelson and Mr. McCoy have worked on numerous projects together since 1979 and share co-inventor positions on various patents.

Term of Office

Our directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

Family Relationships

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

Table of Contents

Involvement in Certain Legal Proceedings

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Committees of the Board

Our company currently does not have nominating, compensation or audit committees or committees performing similar functions nor does our company have a written nominating, compensation or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the functions of such committees can be adequately performed by the board of directors.

Our company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our CEO and director, Randall McCoy, at the address appearing on the first page of this annual report.

Code of Ethics

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the Code of Ethics is attached to our Annual Report on Form 10-K for the year ended September 30, 2011 as Exhibit 14.1.

Table of Contents

Item 11. Executive Compensation

Compensation Discussion and Analysis

Employment Agreement with Randall McCoy

On July 16, 2010, we entered into an employment agreement with Mr. Randall McCoy. The employment agreement has a three-year term that automatically extends in three-year increments unless notice of non-renewal is given by either party at least ninety (90) days prior to the expiration of the then current term.

The July 16, 2010, employment agreement provided for an initial annual base salary of $250,000. Under an addendum to the employment agreement, however, dated August 2, 2010, Mr. McCoy will earn an annual base salary of $125,000 until such time as we achieve a positive net income for the preceding calendar quarter as determined in accordance with GAAP and reported in our financial statements filed with the Securities and Exchange Commission under the Securities and Exchange Act of 1934, as amended. Immediately upon our attaining such positive net income, Mr. McCoy’s annual base salary will be increased to $250,000 as stated in the July 16, 2010 employment agreement.

The annual base salary will be reviewed each year by our board of directors (or compensation committee, if we then have one), but cannot be decreased from the amount in effect in the previous year. Pursuant to the employment agreement, Mr. McCoy is eligible for an annual bonus determined by our board of directors (or compensation committee, if any). The employment agreement also provides that Mr. McCoy is eligible to participate in our equity incentive plans and other employee benefit programs.

Mr. McCoy’s employment agreement imposes on him post-termination non-competition, non-solicitation and confidentiality obligations. Under the agreement, he agrees not to compete with our business in the United States, subject to certain limited exceptions, for a period of one year after termination of his employment. Mr. McCoy further agrees, for a period of one year after termination of his employment, to refrain from (i) soliciting, inducing, encouraging or attempting to induce or encourage any employee, contractor or consultant of the Company to terminate his or her employment or relationship with Company, or to breach any other obligation to Company; and (ii) soliciting, interfering with, disrupting, altering or attempting to disrupt or alter the relationship, contractual or otherwise, between the Company and any other person including, without limitation, any consultant, contractor, customer, potential customer, or supplier of the Company. He also agrees to maintain the confidentiality of all confidential or proprietary information of our company, and assign to us any inventions which pertain to or relate to our business or any of the work or businesses carried on by us that are discovered, conceived, reduced to practice, developed, made or produced by him during and as a result of his employment.

The employment agreement provides for payments and benefits upon termination of employment in addition to those previously accrued. If Mr. McCoy is terminated due to death, the salary payable to Mr. McCoy thereunder (in addition to items previously accrued, but excluding medical plan and other benefits) shall continue to be paid at the then current rate for three (3) months after the termination of employment in accordance with normal Company payroll practices. In addition, any bonuses actually earned prior to the termination (including, as reasonably determined by the Board of Directors or its Compensation Committee, a pro-rated amount of any annual bonus for the portion of the fiscal year during which termination takes place) shall be paid to Mr. McCoy.

In the event of the termination of Mr. McCoy’s employment due to disability, the salary payable there under (inclusive of paid medical plan then in effect and available, if any) shall continue to be paid at the then current rate for three (3) months after the termination of employment in accordance with normal Company payroll practices; provided, however, that the Company may deduct from such payments the amount of any and all disability insurance benefits paid during such three-month period with respect to Mr. McCoy that were paid for by the Company during any period for which payment was made by the Company during the term of the and prior to the termination. In addition, any bonuses actually earned prior to the termination (including, as reasonably determined by the Board of Directors or its Compensation Committee, a pro-rated amount of any annual bonus for the portion of the fiscal year during which termination takes place) which shall be paid to Mr. McCoy.

The table below summarizes all compensation awarded to, earned by, or paid to our officers for all services rendered in all capacities to us for our fiscal years ended September 30, 2022 and 2021.

SUMMARY COMPENSATION TABLE

Name and principal position

Year

Salary ($)

Bonus

($)

Stock

Awards

($)

Option

Awards

($)

Non-Equity

Incentive Plan

Compensation

($)

Nonqualified

Deferred

Compensation

Earnings ($)

All Other

Compensation

($)

Total

($)

Randall McCoy

Chief Executive Officer, Principal Executive Officer and Director

2022

2021

$250,000¹⁾

$250,000(2)

$250,000
$250,000

John J. Weber

Chief Financial Officer and Director

2022

2021

$125,000⁽⁵⁾

$125,000⁽⁶⁾

$125,000

Dr. J. Roy Nelson Chief Science Officer

2022

2021

$150,000⁽³⁾

$150,000⁽⁴⁾

$ 150,000

$150,000

	(1)	Of the $250,000 in salary to Mr. McCoy, $250,000 remains unpaid as accrued compensation.
	(2)	Of the $250,000 in salary to Mr. McCoy, $250,000 remains unpaid as accrued compensation.
	(3)	Of the $150,000 in salary to Mr. Nelson, $150,000 remains unpaid as accrued compensation.
	(4)	Of the $150,000 in salary to Mr. Nelson, $150,000 remains unpaid as accrued compensation.
	(5)	Of the $125,000 in salary to Mr. Weber, $125,000 remains unpaid as accrued compensation.
	(6)	Of the $125,000 in salary to Mr. Weber, $125,000 remains unpaid as accrued compensation.

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The table below summarizes all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officer as of September 30, 2022.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
	OPTION AWARDS									STOCK AWARDS
Name	Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)		Option Exercise Price ($)		Option Expiration Date (1)		Number of Shares or Units of Stock That Have Not Vested (#)		Market Value of Shares or Units of Stock That Have Not Vested ($)		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)		Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#)
Randall McCoy		885,672		—		—	$	0.035	12/31/23			—		—		—	—
John J. Weber		885,672		—		—	$	0.035	12/31/23			—		—		—	—
John J. Weber		10,000,000		—		—	$	0.02	12/31/23			—		—		—	—

(1) On December 31, 2018, the Board extended the term of the options to December 31, 2023.

Director Compensation

There has been no director compensation over the past three years.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of January 6, 2020, certain information as to shares of our common stock owned by (i) each person known by us to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, and (iii) all of our executive officers and directors as a group.

Unless otherwise indicated below, to our knowledge, all persons listed below have sole voting and investment power with respect to their shares of Common Stock, except to the extent authority is shared by spouses under applicable law. Unless otherwise indicated below, each entity or person listed below maintains an address of 10 High Court, Little Falls, NJ 07424.

The number of shares beneficially owned by each stockholder is determined under rules promulgated by the SEC. The information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting or investment power and any shares as to which the individual or entity has the right to acquire beneficial ownership within 60 days through the exercise of any stock option, warrant or other right. The inclusion in the following table of those shares, however, does not constitute an admission that the named stockholder is a direct or indirect beneficial owner.

Beneficial owner	Number of shares beneficially owned ⁽¹⁾			Percentage Owned⁽²⁾
Officers and Directors
Randall McCoy		18,707,313	⁽³⁾		12.19	%
John J. Weber		10,935,672	⁽⁴⁾		7.12	%
Officers and Directors collectively		29,642,985			19.31	%
5 Percent Shareholders
Christopher Brown 100 N Tryon St. #4700 Charlotte, NC 28200		10,000,000			6.52	%

(1) Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person’s spouse) with respect to all shares of common stock listed as owned by that person or entity.

(2) A total of 162,333,050 shares of the Company’s common stock and Series A Convertible Preferred Stock, on an as converted basis, are considered to be outstanding pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934.

(3) Includes 17,821,641 shares of common stock held in his name and options to purchase 885,672 shares of common stock.

(4) Includes 50,000 shares of common stock held in his name and options to purchase 10,885,672 shares of common stock.

Table of Contents

Item 13. Certain Relationships and Related Transactions, and Director Independence

Other than the transactions described below and under the heading “Executive Compensation” (or with respect to which such information is omitted in accordance with SEC regulations), since October 1, 2012 there have not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a participant in which the amount involved exceeded or will exceed $120,000, and in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest:

Our principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

We also maintain an office in Pennington, New Jersey, which is the materials and testing laboratory. This office is owned by Materials Testing Laboratory, and the principal is an employee. In 2016, we entered into a supply agreement to supply collagen scaffolds from a company owned by the same employee.

We have an employment agreement with our CEO, Randall McCoy, as discussed above.

Randall McCoy, our Chief Executive Officer, made advances to us. The loans to not bear interest and are due on demand. At September 30, 2022 and 2021, the loan balance was $4,500 and $4,500, respectively.

John Weber, our Chief Financial Officer, made advances to us. The loans do bear interest at 5% per annum and are due on demand. At September 30, 2022 and 2021, the loan balance was $335,683 and $335,683 respectively.

Randall McCoy and John Weber were principals and partners in Pure Med Farma, a Limited Liability Company which we have engaged to provide our Closed Herd collagen, see discussion above.

Roy Nelson, our Chief Science Officer, made advances to us. The loans do not bear interest and are due on demand. At September 30, 2022 and 2021, the loan balance was $26,935 and $26,935, respectively.

Director Independence

We are not a “listed issuer” within the meaning of Item 407 of Regulation S-K and there are no applicable listing standards for determining the independence of our directors.

Item 14. Principal Accounting Fees and Services

We do not have an audit committee. Our Board of Directors pre-approves all services, including both audit and non-audit services, provided by our independent accountants. For audit services, each year the independent auditor provides our Board of Directors with an engagement letter outlining the scope of the audit services proposed to be performed during the year, which must be formally accepted by the Board of Directors before the audit commences. The independent auditor also submits an audit services fee proposal, which also must be approved by the Board of Directors before the audit commences.

We are filing this annual report without our auditors’ audit opinion of our financial statements for the years ended September 30, 2022 and 2021. Our reason for doing this is simply that we cannot afford at this time to pay our auditor for past due services on prior filings or to pay the costs necessary for this current filing. Instead, we have provided herein information as typically presented in our 10K annual report, including financial information, which has not been audited by any independent public accounting firm. Our auditor is N/A and their firm ID is 9999. The firm is located at N/A.

As a result, we have not included a schedule of audit fees related to fiscal years ended September 30, 2022 and 2021.

We intend, if and when able, to file an amendment to this 10K filing with such audited information. We are unaware at this time when, if ever, we will obtain the necessary funding for this amended filing, but we will continue to provide such information to investors as and when we are able through either this SEC EDGAR filing process and/or through postings on our website as things change.

Table of Contents

PART IV

Item 15. Exhibits, Financial Statements Schedules

(a)

Financial Statements and Schedules

The following financial statements and schedules listed below are included in this Form 10-K.

Financial Statements (See Item 8)

(b)

Exhibits

Exhibit Number	Description
3.1	Articles of Incorporation, as amended ⁽¹⁾
3.2	Bylaws, as amended ⁽¹⁾
3.3	Articles of Continuance
10.4	Know-How License and Stock Purchase Agreement ⁽²⁾
10.5	Form of Stock Option Agreement⁽⁵⁾
10.6	Employment Agreement for Randall McCoy⁽⁴⁾
10.7	Asset Purchase Agreement⁽⁶⁾
14.1	Code of Ethics ⁽³⁾
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

	(1)	Incorporated by reference to the Registration Statement on Form SB-2 filed on October 22, 2006; also incorporated by reference to the Current Report on Form 8-K filed on October 29, 2010.
	(2)	Incorporated by reference to the Current Report on Form 8-K/A filed on April 27, 2011.
	(3)	Incorporated by reference to the Annual Report on Form 10-K filed on January 13, 2011.
	(4)	Incorporated by reference to the Current Report on Form 8-K filed on July 22, 2010.
	(5)	Incorporated by reference to the Current Report on Form 8-K filed on May 17, 2011.
	(6)	Incorporated by reference to the Current Report on Form 8-K filed November 17, 2014.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Regenicin, Inc.

By:

/s/ Randall McCoy

Randall McCoy

President, Chief Executive Officer, Principal Executive Officer, and Director

January 13, 2023

In accordance with Section 13 or 15(d) of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

By:

/s/ Randall McCoy

Randall McCoy

President, Chief Executive Officer, Principal Executive Officer, and Director

January 13, 2023

By:

/s/ John J. Weber

John J. Weber

Interim Chief Financial Officer, Principal Financial and Accounting Officer, and Director

January 13, 2023

Table of Contents

EX-3.3 2 ex3_3.htm EX-3.3

STATE OF WYOMING

Office of the Secretary of State

I, EDWARD A. BUCHANAN, Secretary of State of the State of Wyoming, do hereby certify that

Regenicin Inc.

an entity originally organized under the laws of Nevada on September 6, 2007, did on August 31, 2022 apply for a Certificate of Registration and filed Articles of Continuance in the office of the Secretary of State of State of Wyoming.

I further certify that Regenicin Inc. renounced its jurisdiction of formation and is now formed under the laws of the State of Wyoming in accordance with Wyoming statutes.

I have affixed hereto the Great Seal of the State of Wyoming and duly executed this official certificate at Cheyenne, Wyoming on this 31st day of August, 2022.

Filed 8/31/2022

/s/ Edward A. Buchanan

Secretary of State

By: Kaytlynn Whisenhunt

WY Secretary of State

FILED: 08/31/2022 02:59PM

ID: 2022-001155074

APPLICATION FOR PROFIT CORPORATE

ARTICLES OF CONTINUANCE

Regenicin Inc.

Pursuant to W.S. 17-16-1810 of the Wyoming Business Corporation Act, the undersigned hereby submits

the following Articles of Continuance.

FIRST	The name of the corporation is Regenicin Inc.

SECOND	The laws in which it was incorporated under: Nevada

THIRD	The date of its incorporation is: September 6th, 2007

FOURTH	The Corporation is to have perpetual existence.

FIFTH	The mailing address where correspondence and annual reports can be sent 1712 Pioneer Ave Ste. 500 Cheyenne, WY 82001

SIXTH	The address of its principal office is: 1712 Pioneer Ave Ste. 500 Cheyenne, WY 82001

SEVENTH	The registered agent for this corporation shall be: Capital Administrations, LLC The address of said agent, and, the registered or statutory address of this corporation in the state of Wyoming, shall be: 1712 Pioneer Ave. Suite 115 Cheyenne, WY 82001

EIGHTH	The purpose or purposes of the corporation which it proposes to pursue in the transaction of business in this state: (A) To do all things necessary or convenient to carry out its business and affairs, including without limitation power to:

(B) Sue and be sued, complain and defend in its corporate name;

(C) Have a corporate seal, which may be altered at will, and to use it, or a facsimile of it, by impressing or affixing it or in any other manner reproducing it;

(D) Make and amend bylaws, not inconsistent with its articles of incorporation or with the laws of this state, for managing the business and regulating the affairs of the corporation;

(E) Purchase, receive, lease, or otherwise acquire, and own, hold, improve, use, and otherwise deal with, real or personal property, or any legal or equitable interest in property, wherever located;

(F) Sell, convey, mortgage, pledge, lease, exchange, and otherwise dispose of all or any part of its property;

(G) Purchase, receive, subscribe for, or otherwise acquire; own, hold, vote, use, sell, mortgage, lend, pledge, or otherwise dispose of; and deal in and with shares or other interests in, or obligations of, any other entity;

(H) Make contracts and guarantees, incur liabilities, borrow money, issue its notes, bonds, and other obligations which may be convertible into or include the option to purchase other securities of the corporation, and secure any of its obligations by mortgage or pledge of any of its property, franchises, or income;

(I) Lend money, invest and reinvest its funds, and receive and hold real and personal property as security for repayment;

(J) Be a promoter, partner, member, associate, or manager of any partnership, joint venture, trust, or other entity;

(K) Conduct its business, locate offices, and exercise the powers granted by this act within or without this state;

(L) Elect directors and appoint officers, employees, and agents of the corporation, define their duties, fix their compensation, and lend them money and credit;

(M) Pay pensions and establish pension plans, pension trusts, profit sharing plans, share bonus plans, share option plans, and benefit or incentive plans for any or all of its current or former directors, officers, employees, and agents;

(N) Make donations for the public welfare or for charitable, scientific, or educational purposes;

(O) Transact any lawful business; and

(P) Make payments or donations, or do any other act, not inconsistent with law, that furthers the business and affairs of the corporation.

NINTH

The names and respective addresses of its officers and directors are:

President: Dr. J Roy Nelson 1712 Pioneer Ave Ste. 500, Cheyenne, WY 82001

Secretary: Dr. J Roy Nelson 1712 Pioneer Ave Ste. 500, Cheyenne, WY 82001

Treasurer: Dr. J Roy Nelson 1712 Pioneer Ave Ste. 500, Cheyenne, WY 82001

Director: Dr. J Roy Nelson 1712 Pioneer Ave Ste. 500, Cheyenne, WY 82001

TENTH

The aggregate number of shares or other ownership units which it has the authority to issue, itemized by classes, par value of shares, shares without par value and series, if any, within a class is:

Number of Shares 200,000,000

Class Common

Series

Par Value per Share $0.001

Number of Shares 4,500,000

Class Preferred

Series

Par Value per Share $0.001

Number of Shares 5,500,000

Class Preferred

Series A Convertible

Par Value per Share $0.001

ELEVENTH

The aggregate number of issued shares or other ownership units itemized by classes, par value of shares, shares without par value and series, if any, within a class is:

Number of Shares 153,483,050

Class Common

Series

Par Value per Share $0.001

TWELFTH

The Corporation accepts the Constitution of this state in compliance with the requirements of Article 10, Section 5 of the Wyoming Constitution.

Certification. I do consent on behalf of the business entity to accept electronic service of process at the required email address provided under the circumstances specified in W.S. 17-28-104(e).

Dated this 26th day of August, 2022

/s/ Jasmine James

Jasmine James, on behalf of Capital Administrations, LLC

Authorized Agent for Regenicin Inc.

tax@wyomingcompany.com

State of Wyoming

County of Laramie

I, DeAnna Montemayor, Notary Public, do hereby certify that on this 26th day of August, 2022, personally appeared before me Jasmine James,

In witness whereof, I have hereunto set my hand and seal this 26th day of August, 2022.

/s/ DeAnna Montemayor

My Commission Expires: 04/30/2028

CONSENT TO

APPOINTMENT BY REGISTERED AGENT

Capital Administrations, LLC, located at 1712 Pioneer Ave. Ste. 115, Cheyenne, WY,

82001, voluntarily consents to serve as the registered agent for Regenicin Inc., on the date

shown below;

II.

The undersigned by and on behalf of Capital Administrations, LLC, hereby certify that it is

in compliance with the requirements of W.S. 17-28-101 through W.S. 17-28-111.

Dated this 26th day of August, 2022.

/s/ Jasmine James

Jasmine James, on behalf of

Capital Administrations, LLC, Registered Agent

Email: tax@wvomingcompany.com

Daytime Phone: 307-632-3333

RESOLUTION

CONTINUANCE

Regenicin Inc.

We, the undersigned, constituting all of the officers/directors of the above named

Company, do hereby authorize the continuance of the Company into Wyoming.

DATED: August 22, 2022

J. Roy Nelson

Print Name

Controller

Print Title

/s/ J. Roy Nelson

Signature

BARBARA K. CEGAVSKE Secretary of State

KIMBERLEY PERONDI

Deputy Secretary for

Commercial Recordings

STATE OF NEVADA

OFFICE OF THE

SECRETARY OF STATE

Commercial Recordings & Notary Division 202 N. Carson Street

Carson City, NV 89701

Telephone (775) 684-5708

Fax (775) 684-7138

North Las Vegas City Hall

2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880

Fax (702) 486-2888

	Certified Copy
		08/24/2022 09:51:19 AM
Work Order Number:	W2002082400560-2333613
Reference Number:	20222569249
Through Date:	08/24/2022 09:51:19 AM
Corporate Name:	REGENICIN, INC.

The undersigned filing officer hereby certifies that the attached copies are true and exact

copies of all requested statements and related subsequent documentation filed with the

Secretary of State's Office, Commercial Recordings Division listed on the attached report.

Document Number	Description	Number of Pages
20110384833-43	Certificate of Designation - 05/24/2011	7
20100821883-03	Amendment – 11/01/2010	2
20100533452-85	Certificate Pursuant to NRS 78.209 – 07/19/2010	1
20070614148-43	Articles of Incorporation – 09/06/2007	5

Certified By: Electronically Certified

Certificate Number: B202208252951198

You may verify this certificate

online at http://www.nvsos.gov

Respectfully,

/s/ Barbara K. Cegavske

Nevada Secretary of State

ROSS MILLER

Secretary of State

206 North Carson Street

Carson City, Nevada 89701-4299

(775) 684 5708

Website: secretaryofstate.biz

	Articles of Incorporation (PURSUANT TO NRS 78)
		ABOVE SPACE IS FOR OFFICE USE ONLY
1.	Name of Corporation:	Windstar
2.	Resident Agent Name and Street Address: (must be a Nevada address where process may be served)	Nevada Agency and Trust Company
		Name
		50 West Liberty Street, Ste 880			Reno					NV	89501
		Street Address			City					ST	Zip Code

		Optional Mailing Address			City					ST	Zip Code
3.	Shares: (number of shares corporation authorized to issue)	Number of shares with par value:		100,000,000	Par value: $		0.001		Number of shares without par value:
4.	Names & Addresses of Board of Directors/Trustees: (attach additional page if there is more than 3 directors/trustees)	1.	Siew mee Fam
			Name
		50 West Liberty Street, Suite 880				Reno				NV	89501
		Street Address				City				ST	Zip Code
		2.	Sze Yein Wong
			Name
		50 West Liberty Street, Suite 880				Reno				NV	89501
		Street Address				City				ST	Zip Code
		3.
			Name

		Street Address				City				ST	Zip Code
5.	Purpose: (optional-see instructions)	The purpose of this Corporation shall be: Any lawful business under the State of Nevada
6.	Name, Address and Signature of Incorporator. (attach additional page if there is more than 1 incorporator)	Siew mee Fam						/s/ Siew mee Fam
		Name						Signature
		50 West Liberty Street, Suite 880				Reno		NV			89501
		Street Address				City		ST			Zip Code
7.	Certificate of Acceptance of Appointment of Resident Agent:	I hereby accept appointment as Resident Agent for the above named corporation.
		/s/ Nevada Agency and Trust Company								9/6/2007
		Authorized Signature of R.A. or On Behalf of R.A. Company								Date

This form must be accompanied by appropriate fees.

Nevada Secretary of State Form 78 Articles 2007

Revised on: 01/01/07

ARTICLES OF INCORPORATION

WINDSTAR INC.

ARTICLE I

NAME

The name of the corporation shall be Windstar Inc. (hereinafter, the “Corporation”).

ARTICLE II

REGISTERED OFFICE

The initial office of the Corporation shall be 50 West Liberty Street, Suite 880, Reno, NV 89501. The initial registered agent of the Corporation shall be Nevada Agency and Trust Company at 50 West Liberty Street, Suite 880, Reno, NV 89501. The Corporation may, from time to time, in the manner provided by law, change the resident agent and the registered office within the State of Nevada. The Corporation may also maintain an office or offices for the conduct of its business, either within or without the State of Nevada.

ARTICLE III

CAPITAL STOCK

Section 1. Authorized Shares. The aggregate number of shares which the Corporation shall have authority to issue is one hundred million (100,000,000) shares, consisting of two classes to be designated, respectively, "Common Stock" and "Preferred Stock," with all of such shares having a par value of $.001 per share. The total number of shares of Common Stock that the Corporation shall have authority to issue is ninety million (90,000,000) shares. The total number of shares of Preferred Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed by resolution of the board of directors pursuant to Section 3 of this Article III.

Section 2. Common Stock.

(a) Dividend Rate. Subject to the rights of holders of any Preferred Stock having preference as to dividends and except as otherwise provided by these Articles of Incorporation, as amended from time to time (hereinafter, the "Articles") or the Nevada Revised Statues (hereinafter, the “NRS”), the holders of Common Stock shall be entitled to receive dividends when, as and if declared by the board of directors out of assets legally available therefor.

(b) Voting Rights. Except as otherwise provided by the NRS, the holders of the issued and outstanding shares of Common Stock shall be entitled to one vote for each share of Common Stock. No holder of shares of Common Stock shall have the right to cumulate votes.

(c) Liquidation Rights. In the event of liquidation, dissolution, or winding up of the affairs of the Corporation, whether voluntary or involuntary, subject to the prior rights of holders of Preferred Stock to share ratably in the Corporation's assets, the Common Stock and any shares of Preferred Stock which are not entitled to any preference in liquidation shall share equally and ratably in the Corporation's assets available for distribution after giving effect to any liquidation preference of any shares of Preferred Stock. A merger, conversion, exchange or consolidation of the Corporation with or into any other person or sale or transfer of all or any part of the assets of the Corporation (which shall not in fact result in the liquidation of the Corporation and the distribution of assets to stockholders) shall not be deemed to be a voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation.

(d) No Conversion, Redemption, or Preemptive Rights. The holders of Common Stock shall not have any conversion, redemption, or preemptive rights.

(e) Consideration for Shares. The Common Stock authorized by this Article shall be issued for such consideration as shall be fixed, from time to time, by the board of directors.

Section 3. Preferred Stock.

(a) Designation. The board of directors is hereby vested with the authority from time to time to provide by resolution for the issuance of shares of Preferred Stock in one or more series not exceeding the aggregate number of shares of Preferred Stock authorized by these Articles, and to prescribe with respect to each such series the voting powers, if any, designations, preferences, and relative, participating, optional, or other special rights, and the qualifications, limitations, or restrictions relating thereto, including, without limiting the generality of the foregoing: the voting rights relating to the shares of Preferred Stock of any series (which voting rights, if any, may be full or limited, may vary over time, and may be applicable generally or only upon any stated fact or event); the rate of dividends (which may be cumulative or noncumulative), the condition or time for payment of dividends and the preference or relation of such dividends to dividends payable on any other class or series of capital stock; the rights of holders of Preferred Stock of any series in the event of liquidation, dissolution, or winding up of the affairs of the Corporation; the rights, if any, of holders of Preferred Stock of any series to convert or exchange such shares of Preferred Stock of such series for shares of any other class or series of capital stock or for any other securities, property, or assets of the Corporation or any subsidiary (including the determination of the price or prices or the rate or rates applicable to such rights to convert or exchange and the adjustment thereof, the time or times during which the right to convert or exchange shall be applicable, and the time or times during which a particular price or rate shall be applicable); whether the shares of any series of Preferred Stock shall be subject to redemption by the Corporation and if subject to redemption, the times, prices, rates, adjustments and other terms and conditions of such redemption. The powers, designations, preferences, limitations, restrictions and relative rights may be made dependent upon any fact or event which may be ascertained outside the Articles or the resolution if the manner in which the fact or event may operate on such series is stated in the Articles or resolution. As used in this section "fact or event" includes, without limitation, the existence of a fact or occurrence of an event, including, without limitation, a determination or action by a person, government, governmental agency or political subdivision of a government. The board of directors is further authorized to increase or decrease (but not below the number of such shares of such series then outstanding) the number of shares of any series subsequent to the issuance of shares of that series. Unless the board of directors provides to the contrary in the resolution which fixes the characteristics of a series of Preferred Stock, neither the consent by series, or otherwise, of the holders of any outstanding Preferred Stock nor the consent of the holders of any outstanding Common Stock shall be required for the issuance of any new series of Preferred Stock regardless of whether the rights and preferences of the new series of Preferred Stock are senior or superior, in any way, to the outstanding series of Preferred Stock or the Common Stock.

(b) Certificate. Before the Corporation shall issue any shares of Preferred Stock of any series, a certificate of designation setting forth a copy of the resolution or resolutions of the board of directors, and establishing the voting powers, designations, preferences, the relative, participating, optional, or other rights, if any, and the qualifications, limitations, and restrictions, if any, relating to the shares of Preferred Stock of such series, and the number of shares of Preferred Stock of such series authorized by the board of directors to be issued shall be made and signed by an officer of the corporation and filed in the manner prescribed by the NRS.

Section 4. Non-Assessment of Stock. The capital stock of the Corporation, after the amount of the subscription price has been fully paid, shall not be assessable for any purpose, and no stock issued as fully paid shall ever be assessable or assessed, and the Articles shall not be amended in this particular. No stockholder of the Corporation is individually liable for the debts or liabilities of the Corporation.

ARTICLE IV

DIRECTORS AND OFFICERS

Section 1. Number of Directors. The members of the governing board of the Corporation are styled as directors. The board of directors of the Corporation shall be elected in such manner as shall be provided in the bylaws of the Corporation. The board of directors shall consist of at least one (1) individual and not more than thirteen (13) individuals. The number of directors may be changed from time to time in such manner as shall be provided in the bylaws of the Corporation.

Section 2. Initial Directors. The name and post office box or street address of the director(s) constituting the initial board of directors is:

Name Address

Siew Mee Fam 50 West Liberty Street, Suite 880, Reno, NV 89501

Section 3. Limitation of Liability. The liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS. If the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS, as so amended from time to time.

Section 4. Payment of Expenses. In addition to any other rights of indemnification permitted by the laws of the State of Nevada or as may be provided for by the Corporation in its bylaws or by agreement, the expenses of officers and directors incurred in defending any threatened, pending, or completed action, suit or proceeding (including without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, involving alleged acts or omissions of such officer or director in his or her capacity as an officer or director of the Corporation or member, manager, or managing member of a predecessor limited liability company or affiliate of such limited liability company or while serving in any capacity at the request of the Corporation as a director, officer, employee, agent, member, manager, managing member, partner, or fiduciary of, or in any other capacity for, another corporation or any partnership, joint venture, trust, or other enterprise, shall be paid by the Corporation or through insurance purchased and maintained by the Corporation or through other financial arrangements made by the Corporation, as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not entitled to be indemnified by the Corporation. To the extent that an officer or director is successful on the merits in defense of any such action, suit or proceeding, or in the defense of any claim, issue or matter therein, the Corporation shall indemnify him or her against expenses, including attorneys' fees, actually and reasonably incurred by him or her in connection with the defense. Notwithstanding anything to the contrary contained herein or in the bylaws, no director or officer may be indemnified for expenses incurred in defending any threatened, pending, or completed action, suit or proceeding (including without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, that such director or officer incurred in his or her capacity as a stockholder, including, but not limited to, in connection with such person being deemed an Unsuitable Person (as defined in Article VII hereof).

Section 5. Repeal And Conflicts. Any repeal or modification of Sections 3 or 4 above approved by the stockholders of the Corporation shall be prospective only, and shall not adversely affect any limitation on the liability of a director or officer of the Corporation existing as of the time of such repeal or modification. In the event of any conflict between Sections 3 or 4 above and any other Article of the Articles, the terms and provisions of Sections 3 or 4 above shall control.

ARTICLE V

COMBINATIONS WITH INTERESTED STOCKHOLDERS

At such time, if any, as the Corporation becomes a "resident domestic corporation", as that term is defined in NRS 78.427, the Corporation shall not be subject to, or governed by, any of the provisions in NRS 78.411 to 78.444, inclusive, as may be amended from time to time, or any successor statute.

ARTICLE VI

BYLAWS

The board of directors is expressly granted the exclusive power to make, amend, alter, or repeal the bylaws of the Corporation pursuant to NRS 78.120.

IN WITNESS WHEREOF, the Corporation has caused these articles of incorporation to be executed in its name by its Incorporator on August 8, 2007.

/s/ Siew Mee Fam

Siew Mee Fam

ROSS MILLER Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz

Certificate of Change Pursuant to NRS 78.209

USE BLACK INK ONLY – DO NOT HIGHLIGHT	ABOVE SPACE IS FOR OFFICE USE ONLY

Certificate of Change filed Pursuant to NRS 78.209 For Nevada Profit Corporations


1. Name of corporation:
Regenicin, Inc.

2. The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any required approval of the stockholders.

3. The current number of authorized shares at the par value, if any, of each class or series, if any, of shares before the change:
90,000,000 shares of common stock with $0.001 par value 10,000,000 shares of common stock with $0.001 par value

4. The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:
90,000,000 shares of common stock with $0.001 par value 10,000,000 shares of common stock with $0.001 par value

5. The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issue share of the same class or series:
34 shares issued for every 1 outstanding

6. The provisions, if any, for the issuance of fractional shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the percentage of outstanding shares affected thereby:
fractional shares will be rounded to the nearest whole number

7. Effective date of filing (optional):

8. Officer Signature: X /s/ Randall E. McCoy

ROSS MILLER

Secretary of State

206 North Carson Street

Carson City, Nevada 89701-4299

(775) 684 5708

Website: secretaryofstate.biz

Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390)
USE BLACK INK ONLY-DO NOT HIGHLIGHT		ABOVE SPACE IS FOR OFFICE USE ONLY
Certificate of Amendment to Articles of Incorporation
For Nevada Corporations
(Pursuant to NRS 78.385 and 78.390—After Issuance of Stock)

1.	Name of corporation:
	Regenicin, Inc.

2.	The articles have been amended as follows (provide article numbers, if available):
	ARTICLE III: CAPITAL STOCK Section 1. Authorized Shares. The aggregate number of shares which the Corporation shall have authority to issue is two hundred ten million (210,000,000) shares, consisting of two classes to be designated, respectively, "Common Stock" and "Preferred Stock," with all of such shares having a par value of $.001 per share. The total number of shares of Common Stock that the Corporation shall have authority to issue is two hundred million (200,000,000) shares. The total number of shares of Preferred Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed by resolution of the board of directors pursuant to Section 3 of this Article III.

3.	The vote by which the stockholders holding shares in the corporationentitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:
	majority

4.	Effective date of filing (optional):

5.	Signatures (required)

	X /s/ Randall McCoy
	Signature
* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

Section 1. Authorized Shares. The aggregate number of shares which the Corporation shall have authority to issue is two hundred ten million (210,000,000) shares, consisting of two classes to be designated, respectively, "Common Stock" and "Preferred Stock," with all of such shares having a par value of $.001 per share. The total number of shares of Common Stock that the Corporation shall have authority to issue is two hundred million (200,000,000) shares. The total number of shares of Preferred Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed by resolution of the board of directors pursuant to Section 3 of this Article III.

ROSS MILLER

Secretary of State

206 North Carson Street

Carson City, Nevada 89701-4299

(775) 684 5708

Website: secretaryofstate.biz

Certificate of Designation (PURSUANT TO NRS 78.1955)
USE BLACK INK ONLY-DO NOT HIGHLIGHT		ABOVE SPACE IS FOR OFFICE USE ONLY
Certificate of Designation For
For Nevada Corporations
(Pursuant to NRS 78.1955)

1.	Name of corporation:
	Regenicin, Inc.

2.	By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock.
	The following is a statement of the powers, designations, preferences, limitations, restrictions and relative rights of a series of preferred stock of Regenicin, Inc. a Nevada corporation (the “Corporation”), as authorized and ratified on May 10, 2011, by the board of directors of the Corporation (the “Board”), for the purposes of confirming a series of the Corporation’s authorized preferred stock, $.00 par value per share (“Preferred Stock”), designated as Series A Convertible Preferred Stock, and identifying the relative rights and preferences thereof: See Attached.

3.	Effective date of filing (optional):

4.	Signatures (required)

	X /s/ Randall McCoy
	Signature

______________________________________

CERTIFICATE OF DESIGNATION

REGENICIN, INC.

Pursuant to Section 78.1955 of the

Nevada Revised Statutes

______________________________________

SERIES A CONVERTIBLE PREFERRED STOCK

On behalf of Regenicin, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation (the “Board”):

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the “Articles of Incorporation”), there hereby is created, out of the ten million (10,000,000) shares of preferred stock, par value $.001 per share, of the Corporation authorized by Article Fourth of the Articles of Incorporation (“Preferred Stock”), Series A Convertible Preferred Stock, consisting of three million five hundred thousand (3,500,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

The specific powers, preferences, rights and limitations of the Series A Convertible Preferred Stock are as follows:

1. Designation; Rank. This series of Preferred Stock shall be designated and known as “Series A Convertible Preferred Stock.” The number of shares constituting the Series A Convertible Preferred Stock shall be three million five hundred thousand (3,500,000) shares. Except as otherwise provided herein, the Series A Convertible Preferred Stock shall, with respect to dividend rights and rights on liquidation, winding up and dissolution, rank senior to the common stock, par value $0.001 per share (the “Common Stock”), and all classes and series of stock of the Corporation now or hereafter authorized, issued or outstanding (collectively, “Junior Securities”).

2. Dividends. The Holders of shares of the Series A Convertible Preferred Stock (each, a “Holder” and collectively, the “Holders”) shall be entitled to receive, when and if declared by the Board of Directors, out of the assets of the Corporation legally available therefore, dividends at the annual rate of 8% on the Stated Value thereof. Dividends shall be cumulative, and will accrue from the date the shares of Series A Convertible Preferred Stock are first issued (“Original Issue Date”), whether or not declared by the Board of Directors, and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends, and shall continue to accrue thereon until paid in full or converted into shares of Common Stock in accordance with Section 4 or 5 of this Designation. Dividends shall be payable quarterly in arrears to the Holders of shares of Series A Convertible Preferred Stock at the option of the Corporation in cash or Common Stock. No dividends or other distribution shall be paid on any Junior Securities unless and until the aforementioned 8% cumulative dividend is paid to current on each outstanding share of Series A Convertible Preferred Stock.

3. Liquidation Preference.

(a) In the event of any dissolution, liquidation or winding up of the Corporation (a “Liquidation”), whether voluntary or involuntary, the Holders of Series A Convertible Preferred Stock shall be entitled to receive out of the assets of the Corporation, before any payment or distribution shall be made in respect of any Junior Securities, cash in an amount equal to $1.00 (the “Stated Value”) for each one (1) share of Series A Convertible Preferred Stock (as adjusted for stock splits, combinations, reorganizations and the like) plus an amount equal to all accrued but unpaid dividends thereon to the date of such payment. If upon the Liquidation, the assets to be distributed among the Holders of the Series A Convertible Preferred Stock are insufficient to permit the payment to such Holders of the full liquidation preference for their shares, then the entire assets of the Corporation legally available for distribution shall be distributed pro rata among the Holders of the Series A Convertible Preferred Stock.

(b) A sale of all or substantially all of the Corporation’s assets or an acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Corporation (a “Change in Control Event”), shall not be deemed to be a Liquidation for purposes of this Designation.

(c) If upon any Liquidation, whether voluntary or involuntary, payment shall have been made to the Holders of Series A Convertible Preferred Stock of the full preferential amount to which they shall be entitled pursuant to Section 3(a) of this Designation, the entire remaining assets, if any, of the Corporation available for distribution to stockholders shall be distributed to the holders of Junior Securities or Common Stock, as the case may be.

(d) The Corporation shall give each Holder of Series A Preferred Convertible Stock written notice of any Liquidation not later than thirty (30) days prior to any meeting of stockholders to approve such Liquidation or, if no meeting is to be held, not later than forty-five (45) days prior to the date of such Liquidation.

4. Optional Conversion of Series A Convertible Preferred Stock. The Holders of Series A Convertible Preferred Stock shall have conversion rights as follows:

(a) Conversion Right. Each share of Series A Convertible Preferred Stock shall be convertible at the option of the Holder thereof and without the payment of additional consideration by the Holder thereof, at any time, into shares of Common Stock on the Optional Conversion Date (as hereinafter defined) at a conversion rate of ten (10) shares of Common Stock (the “Conversion Rate”) for every one (1) share of Series A Convertible Preferred Stock, subject to adjustment as provided in Section 4 of this Designation.

(b) Mechanics of Optional Conversion. To effect the optional conversion of shares of Series A Convertible Preferred Stock in accordance with Section 4(a) of this Designation, any Holder of record shall make a written demand for such conversion (for purposes of this Designation, a “Conversion Demand”) upon the Corporation at its principal executive offices setting forth therein (i) the certificate or certificates representing such shares, and (ii) the proposed date of such conversion, which shall be a business day not less than fifteen (15) nor more than thirty (30) days after the date of such Conversion Demand (for purposes of this Designation, the “Optional Conversion Date”). Within five days of receipt of the Conversion Demand, the Corporation shall give written notice (for purposes of this Designation, a “Conversion Notice”) to the Holder setting forth therein (i) the address of the place or places at which the certificate or certificates representing any shares not yet tendered are to be converted are to be surrendered; and (ii) whether the certificate or certificates to be surrendered are required to be endorsed for transfer or accompanied by a duly executed stock power or other appropriate instrument of assignment and, if so, the form of such endorsement or power or other instrument of assignment. The Conversion Notice shall be sent by first class mail, postage prepaid, to such Holder at such Holder’s address as may be set forth in the Conversion Demand or, if not set forth therein, as it appears on the records of the stock transfer agent for the Series A Convertible Preferred Stock, if any, or, if none, of the Corporation. On or before the Optional Conversion Date, each Holder of the Series A Convertible Preferred Stock so to be converted shall surrender the certificate or certificates representing such shares, duly endorsed for transfer or accompanied by a duly executed stock power or other instrument of assignment, if the Conversion Notice so provides, to the Corporation at any place set forth in such notice or, if no such place is so set forth, at the principal executive offices of the Corporation. As soon as practicable after the Optional Conversion Date and the surrender of the certificate or certificates representing such shares, the Corporation shall issue and deliver to such Holder, or its nominee, at such Holder’s address as it appears on the records of the stock transfer agent for the Series A Convertible Preferred Stock, if any, or, if none, of the Corporation, a certificate or certificates for the number of whole shares of Common Stock issuable upon such conversion in accordance with the provisions hereof.

(c) No Fractional Shares. No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series A Convertible Preferred Stock. In lieu of any fractional share to which the Holder would be entitled but for the provisions of this Section 4(c) based on the number of shares of Series A Convertible Preferred Stock held by such Holder, the Corporation shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series A Convertible Preferred Stock by the Corporation upon conversion of Series A Preferred Convertible Stock by such Holder.

(d) Reservation of Stock. The Corporation shall at all times when any shares of Series A Preferred Convertible Stock shall be outstanding, reserve and keep available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Series A Convertible Preferred Stock. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all outstanding shares of the Series A Convertible Preferred Stock, the Corporation will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized by unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.

(e) Dividends; Rights. All outstanding shares of Series A Convertible Preferred Stock to be converted pursuant to the Conversion Notice shall, on the Optional Conversion Date, be converted into Common Stock for all purposes, notwithstanding the failure of the Holder thereof to surrender any certificate representing such shares on or prior to such date. On and after the Optional Conversion Date, (i) no such share of Series A Convertible Preferred Stock to be converted pursuant to the Conversion Notice shall be deemed to be outstanding or be transferable on the books of the Corporation or the stock transfer agent, if any, for the Series A Convertible Preferred Stock, and (ii) the Holder of such shares, as such, shall not be entitled to receive any dividends or other distributions, to receive notices or to vote such shares or to exercise or to enjoy any other powers, preferences or rights thereof, other than the right, upon surrender of the certificate or certificates representing such shares, to receive a certificate or certificates for the number of shares of Common Stock into which such shares to be converted pursuant to the Conversion Notice have been converted. On the Optional Conversion Date, all such shares shall be retired and canceled and shall not be reissued.

(f) Consolidation, Merger, Sale, Etc. In case the Corporation shall (a) effect a reorganization, (b) undergo a Change in Control Event, or (c) enter into any plan or arrangement contemplating the dissolution of the Corporation, then, in each such case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made whereby each share of Series A Convertible Preferred Stock shall, after such transaction, be convertible into the kind and number of shares of stock or other securities or property of the Corporation or of the corporation resulting from such transaction, or to which assets shall have been sold in such transaction, to which the Holder of shares of Series A Convertible Preferred Stock would have been entitled if it had held the Common Stock issuable upon the conversion of such shares of Series A Convertible Preferred Stock on the record date, or, if none, immediately prior to such transaction, at the Conversion Rate in effect on such date. The provisions of this Section 4(f) shall similarly apply to successive transactions.

(g) Stock Dividends, Splits, Combinations and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller number, or (iv) increase or decrease the number of shares of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger, consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an “Event”), then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share of Series A Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for such Event.

(h) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Rate pursuant to Section 4 of this Designation, the Corporation at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and cause its principal financial officer to verify such computation and prepare and furnish to each Holder of Series A Convertible Preferred Stock a certificate setting forth such adjustment or readjustment and setting forth in reasonable detail the facts upon which such adjustment or readjustment is based. The Corporation shall, upon the written request at any time of any Holder of Series A Convertible Preferred Stock, furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such adjustments and readjustments; (ii) the Conversion Rate in effect at such time for the Series A Convertible Preferred Stock; and (iii) the number of shares of Common Stock and the amount, if any, of other property that at such time would be received upon the conversion of the Series A Convertible Preferred Stock.

(i) Notices of Record Date. In the event any record date is fixed for the purpose of (i) determining the holders of any class or series of stock or other securities who are entitled to receive any dividend or other distribution or (ii) to effect a Liquidation, the Corporation shall mail to each Holder of Series A Convertible Preferred Stock at least thirty (30) days prior to the record date set forth therein a notice setting forth: (A) such record date and a description of such dividend or distribution; or (B) (1) the date on which any such recapitalization, reorganization, merger, consolidation, disposition, dissolution, liquidation or winding up is expected to become effective; and (2) the time, if any is to be fixed, as to when the Holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable upon such recapitalization, reorganization, merger, consolidation, disposition, dissolution, liquidation or winding up.

(j) Issue Taxes. The converting Holder shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series A Convertible Preferred Stock.

(k) No Impairment. The Corporation will not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under Section 4 of this Designation by the Corporation, but will at all times in good faith assist in carrying out of all the provision of Section 4 of this Designation and in the taking of all such action as may be necessary or appropriate in order to protect the conversion rights of the Holders against impairment.

5. Mandatory Conversion of Series A Convertible Preferred Stock.

(a) If (i) the Common Stock underlying the Series A Convertible Preferred Stock is registered with the Securities and Exchange Commission or eligible for Rule 144, and (ii) the VWAP of the Corporation’s Common Stock is in excess of $1.50 per share for twenty (20) consecutive trading days, then the Corporation shall require that the Holder of any outstanding Series A Convertible Preferred Stock to convert the same into shares of Common Stock at the Conversion Rate.

(b) No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series A Convertible Preferred Stock. In lieu of any fractional share to which the Holder would otherwise be entitled but for the provisions of this Section 5(b), based on the number of shares of Series A Convertible Preferred Stock held by such Holder, the Corporation shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series A Convertible Preferred Stock by the Corporation upon conversion of Series A Convertible Preferred Stock by such Holder.

(c) The Corporation shall give to each Holder of record of Series A Convertible Preferred Stock written notice of mandatory conversion within a reasonable period of time following an event under Section 5(a), setting forth therein: (i) the number of shares of Common Stock into which such Holder’s shares of Series A Convertible Preferred Stock are to be converted based on such Conversion Rate; (ii) the address of the place or places at which the certificate or certificates representing such Holder’s shares of Series A Convertible Preferred Stock are to be surrendered; and (iii) whether the certificate or certificates to be surrendered are required to be endorsed for transfer or accompanied by a duly executed stock power or other appropriate instrument of assignment and, if so, the form of such endorsement or power or other instrument of assignment. Such notice shall be sent by first class mail, postage prepaid, to each Holder of record of Series A Convertible Preferred Stock at such Holder’s address as it appears on the records of the stock transfer agent for the Series A Convertible Preferred Stock, if any, or, if none, of the Corporation. Each Holder of Series A Convertible Preferred Stock shall surrender the certificate or certificates representing all such Holder’s shares, duly endorsed for transfer or accompanied by a duly executed stock power or other instrument of assignment, if the notice so provides, to the Corporation at any place set forth in such notice or, if no such place is so set forth, at the principal executive offices of the Corporation. As soon as practicable after the surrender of the certificate or certificates representing shares of Series A Convertible Preferred Stock, the Corporation shall issue and deliver to each such Holder, or its nominee, at such Holder’s address as it appears on the records of the stock transfer agent for the Series A Convertible Preferred Stock, if any, or, if none, of the Corporation a certificate or certificates for the number of whole shares of Common Stock issuable upon such conversion in accordance with the provisions hereof.

(d) All outstanding shares of Series A Convertible Preferred Stock shall be converted into Common Stock for all purposes, notwithstanding the failure of any Holder or Holders thereof to surrender any certificate representing such shares on or prior to such date. Following an event under Section 5(a), (i) no share of Series A Convertible Preferred Stock shall be deemed to be outstanding or be transferable on the books of the Corporation or the stock transfer agent, if any, for the Series A Convertible Preferred Stock, and (ii) each Holder of Series A Convertible Preferred Stock, as such, shall not be entitled to receive any dividends or other distributions, to receive notices or to vote such shares or to exercise or to enjoy any other powers, preferences or rights in respect thereof, other than the right, upon surrender of the certificate or certificates representing such shares, to receive a certificate or certificates for the number of shares of Common Stock into which such shares shall have been converted. All such shares shall be retired and canceled and shall not be reissued.

6. Redemption. At any time after the issuance of the Series A Convertible Preferred Stock, the Corporation shall have the right to redeem any of the Series A Convertible Preferred Stock upon paying the Stated Value and any accrued but unpaid dividends.

7. Voting.

(a) Except as otherwise expressly provided herein or as required by the law, the Holders of Series A Convertible Preferred Stock and the holders of Common Stock shall vote together and not as separate classes. The Holders of Series A Convertible Preferred Stock shall be entitled to vote with the common stock as if their shares were converted into shares of Common Stock. The Holders of shares of the Series A Convertible Preferred shall be entitled to vote on all matters on which the Common Stock shall be entitled to vote. The Holders shall be entitled to notice of any stockholders’ meeting in accordance with the bylaws of the Corporation.

(b) For so long as at least 25% of the issued Series A Convertible Preferred Stock remain outstanding and not converted, the Corporation shall not, without first obtaining the approval MKM Opportunity Master Fund LLC: (i) adversely affect the rights, preferences or privileges of the Series A Convertible Preferred Stock including pledging any assets, (ii) create or issue any new class or series of shares having rights, preferences or privileges pari passu or senior to the Series A Convertible Preferred Stock, (iii) incur any debt or other obligation including but not limited to accounts payable, accrued but unpaid employee compensation, and other accrued but unpaid ordinary course expenses that exceed $500,000, (iv) amend, waive, or repeal any provision of the Corporation’s Articles of Incorporation or Bylaws in a manner that adversely affects the Series A Convertible Preferred Stock, (v) decrease the authorized size of the Board, (vi) effect any merger, sale, consolidation or reorganization of the Corporation, or (vii) liquidate or dissolve the Corporation.

8. Additional Rights.

(a) For so long as shares of the Series A Convertible Preferred Stock remain outstanding and not converted, the Holders of Series A Convertible Preferred Stock will have the option to purchase up to the maximum of $2,000,000 in additional Units on the same terms as they purchased their original Units for a period of 9 months from the Original Issue Date, except that each share of Series A Convertible Preferred Stock purchased will be convertible into only 6 and 2/3 shares of Common Stock and each warrant will be exercisable at $0.25 per share.

(b) For so long as shares of the Series A Convertible Preferred Stock remain outstanding and not converted, Holders of Series A Convertible Preferred Stock will have the right to participate in any financing of the Corporation for two years from the Original Issue Date based on maintaining their proportionate stake on a fully diluted basis.

(c) For so long as shares of the Series A Convertible Preferred Stock remain outstanding and not converted, Holders of Series A Convertible Preferred Stock will have full ratchet anti-dilution on the shares underlying the Series A Convertible Preferred Stock for three years from the Original Issue Date on any unconverted amounts, on any securities issued below the Conversion Rate, with the exception of shares issued in a Change in Control Event.

IN WITNESS WHEREOF, the undersigned have duly signed this Designation as of this __ day of May 2011.

	Regenicin, Inc.

	By:	/s/ Randall McCoy
		Name: Randall McCoy Title: CEO

EX-31.1 3 ex31_1.htm EX-31.1

CERTIFICATIONS

I, Randall McCoy, certify that;

I have reviewed this annual report on Form 10-K for the year ended September 30, 2022 of Regenicin, Inc (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 13, 2023

/s/ Randall McCoy

By: Randall McCoy

Title: Chief Executive Officer

EX-31.2 4 ex31_2.htm EX-31.2

CERTIFICATIONS

I, John J. Weber, certify that;

I have reviewed this annual report on Form 10-K for the year ended September 30, 2022 of Regenicin, Inc (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 13, 2023

/s/ John J. Weber

By: John J. Weber

Title: Chief Financial Officer

EX-32.1 5 ex32_1.htm EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual Report of Regenicin, Inc (the “Company”) on Form 10-K for the year ended September 30, 2022 filed with the Securities and Exchange Commission (the “Report”), I, Randall McCoy, Chief Executive Officer of the Company, and, I John J. Weber, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Randall McCoy
Name:	Randall McCoy
Title:	Principal Executive Officer and Director
Date:	January 13, 2023

By:	/s/ John J. Weber
Name:	John J. Weber
Title:	Principal Financial Officer and Director
Date:	January 13, 2023

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 7 image_003.jpg GRAPHIC begin 644 image_003.jpg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rgin-20220930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - THE COMPANY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - LICENSE OF RIGHTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - PROMISSORY NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCKHOLDERS’ DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCKHOLDERS’ DEFICIENCY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - THE COMPANY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Income per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - LICENSE OF RIGHTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PROMISSORY NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Value of Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS’ DEFICIENCY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 rgin-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 rgin-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 rgin-20220930_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock [Member] Sale Of Assets [Axis] Sale Agreement [Member] Sale Agreement Amended [Member] Debt Instrument [Axis] Chief Financial Officer [Member] Chief Science Officer [Member] Chief Executive Officer [Member] Notes Payable [Axis] Promissory Note 2 [Member] Statement Equity Component [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Incentive Plan 2010 [Member] Board Member Options [Member] Stock Option Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Firm ID Auditor Location Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Common stock of Amarantus Total current and total assets LIABILITIES AND STOCKHOLDERS' DEFICIENCY CURRENT LIABILITIES Accounts payable Accrued expenses - other (related party of $65,471 and $46,713) Accrued salaries - officers Promissory note payable Convertible promissory note - officer Loan payable Loans payable - officer Total current and total liabilities STOCKHOLDERS' DEFICIENCY Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding Additional paid-in capital Accumulated deficit Less: treasury stock; 4,428,360 shares at par Total stockholders' deficiency Total liabilities and stockholders' deficiency [custom:AccruedLiabilitiesCurrentRelatedParties-0] [custom:SeriesAPreferredStockAtParValue-0] [custom:SeriesASharesAuthorized-0] [custom:SeriesASharesIssued-0] Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Treasury Stock, Shares Income Statement [Abstract] Revenues Operating expenses General and administrative Total operating expenses Other expenses Interest expense related party of $(18,758), $(17,213) Change in unrealized loss on securities Total other expenses Net loss Preferred stock dividends Net loss attributable to common stockholders Loss per share basic Loss per share diluted Weighted average number of shares outstanding basic Weighted average number of shares outstanding diluted Interest Expense, Related Party Statement [Table] Statement [Line Items] Balances at October 1, 2020 Shares, Outstanding, Beginning Balance Balances at September 30, 2021 Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Unrealized loss on investment Accrued interest on loans and notes payable Changes in operating assets and liabilities Accounts payable Accrued expenses - other Accrued salaries - officers Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds of loans from officers Net cash provided by financing activities NET INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] THE COMPANY Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES License Of Rights LICENSE OF RIGHTS Payables and Accruals [Abstract] ACCRUED EXPENSES Loans Payable LOANS PAYABLE Receivables [Abstract] PROMISSORY NOTES PAYABLE Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] STOCKHOLDERS’ DEFICIENCY Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of Consolidation: Going Concern: Income (loss) per share: Financial Instruments and Fair Value Measurement: Use of Estimates: Stock-Based Compensation: Income Taxes: Recently Issued Accounting Pronouncements: Schedule of Income per Common Share Schdule of Income per Common Share Exclusuions #1 Schedule of Accrued Expenses Schedule of Deferred Tax Assets Schedule of Effective Income Tax Rate Schedule of Option Activity Schedule of Value of Options EX-101.PRE 12 rgin-20220930_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Sep. 30, 2022	Dec. 31, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--09-30
Entity File Number	333-146834
Entity Registrant Name	Regenicin, Inc.
Entity Central Index Key	0001412659
Entity Tax Identification Number	27-3083341
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	10 High Court,
Entity Address, City or Town	Little Falls,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07424
City Area Code	973
Local Phone Number	557 8914
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float		$ 1,534,830
Entity Common Stock, Shares Outstanding		153,483,050
Auditor Name	N/A
Auditor Firm ID	9999
Auditor Location	N/A

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
CURRENT ASSETS
Cash	$ 14,569	$ 1,859
Common stock of Amarantus	925	2,750
Total current and total assets	15,493	4,609
CURRENT LIABILITIES
Accounts payable	103,119	93,674
Accrued expenses - other (related party of $65,471 and $46,713)	254,595	234,894
Accrued salaries - officers	4,612,001	4,031,001
Promissory note payable	175,000	175,000
Convertible promissory note - officer	335,683	335,683
Loan payable	10,000	10,000
Loans payable - officer	122,235	82,235
Total current and total liabilities	$ 5,612,633	$ 4,962,487
STOCKHOLDERS' DEFICIENCY
Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding	$ 885	$ 885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding	$ 157,914	$ 157,914
Additional paid-in capital	10,208,339	10,208,339
Accumulated deficit	(15,959,850)	(15,320,588)
Less: treasury stock; 4,428,360 shares at par	(4,428)	(4,428)
Total stockholders' deficiency	(5,597,140)	(4,957,878)
Total liabilities and stockholders' deficiency	$ 15,493	$ 4,609

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Statement of Financial Position [Abstract]
[custom:AccruedLiabilitiesCurrentRelatedParties-0]	$ 65,471	$ 46,713
[custom:SeriesAPreferredStockAtParValue-0]	$ 0.001	$ 0.001
[custom:SeriesASharesAuthorized-0]	5,500,000	5,500,000
[custom:SeriesASharesIssued-0]	885,000	885,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	157,911,410	157,911,410
Common Stock, Shares, Outstanding	153,483,050	153,483,050
Treasury Stock, Shares	4,428,360	4,428,360

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues
Operating expenses
General and administrative	601,179	635,864
Total operating expenses	601,179	635,864
Other expenses
Interest expense related party of $(18,758), $(17,213)	(36,258)	(34,713)
Change in unrealized loss on securities	(1,825)	(25)
Total other expenses	(38,083)	(34,738)
Net loss	(639,262)	(670,602)
Preferred stock dividends	(52,954)	(70,405)
Net loss attributable to common stockholders	$ (692,216)	$ (741,007)
Loss per share basic	$ (0.00)	$ (0.00)
Loss per share diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding basic	153,483,050	153,483,050
Weighted average number of shares outstanding diluted	153,483,050	153,483,050

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Interest Expense, Related Party	$ 18,758	$ 17,213

XML 18 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Balances at October 1, 2020	$ (4,957,878)	$ (4,287,276)
Net loss	(639,262)	(670,602)
Balances at September 30, 2021	(5,597,140)	(4,957,878)
Preferred Stock [Member]
Balances at October 1, 2020	$ 885	885
Shares, Outstanding, Beginning Balance	885,000
Net loss
Balances at September 30, 2021	885	885
Common Stock [Member]
Balances at October 1, 2020	$ 157,914	157,914
Shares, Outstanding, Beginning Balance	157,911,410
Net loss
Balances at September 30, 2021	157,914	157,914
Additional Paid-in Capital [Member]
Balances at October 1, 2020	10,208,339	10,208,339
Net loss
Balances at September 30, 2021	10,208,339	10,208,339
Retained Earnings [Member]
Balances at October 1, 2020	(15,320,588)	(14,649,986)
Net loss	(639,262)	(670,602)
Balances at September 30, 2021	(15,959,850)	(15,320,588)
Treasury Stock [Member]
Balances at October 1, 2020	(4,428)	(4,428)
Net loss
Balances at September 30, 2021	$ (4,428)	$ (4,428)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 19 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (639,262)	$ (670,602)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investment	1,825	25
Accrued interest on loans and notes payable	36,258	34,713
Changes in operating assets and liabilities
Accounts payable	9,443	5,015
Accrued expenses - other	(16,555)	25,743
Accrued salaries - officers	581,000	580,999
Net cash used in operating activities	(27,291)	(24,107)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds of loans from officers	40,000	24,600
Net cash provided by financing activities	40,000	24,600
NET INCREASE IN CASH	12,709	493
CASH - BEGINNING OF PERIOD	1,859	1,366
CASH - END OF PERIOD	14,568	1,859
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for taxes

XML 20 R8.htm IDEA: XBRL DOCUMENT

THE COMPANY

12 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY

NOTE A - THE COMPANY

XML 21 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation:

The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated.

Going Concern:

Income (loss) per share:

The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares:

	2022				2021
Options		—				—

	2022		2021
Options		11,771,344		11,771,344
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		35,712,910		16,784,150
Shares excluded from the calculation of diluted loss per share		56,334,254		37,405,494

Financial Instruments and Fair Value Measurement:

Use of Estimates:

Stock-Based Compensation:

Income Taxes:

Recently Issued Accounting Pronouncements:

XML 22 R10.htm IDEA: XBRL DOCUMENT

LICENSE OF RIGHTS

12 Months Ended

Sep. 30, 2022

License Of Rights

LICENSE OF RIGHTS

NOTE C – LICENSE OF RIGHTS

XML 23 R11.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES

12 Months Ended

Sep. 30, 2022

Payables and Accruals [Abstract]

ACCRUED EXPENSES

NOTE D – ACCRUED EXPENSES

Accrued expenses consisted of the following:

	2022		2021
Professional fees	$	9,186	$	25,743
Interest		245,409		209,151
Accrued expenses	$	254,595	$	234,894

XML 24 R12.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE

12 Months Ended

Sep. 30, 2022

Loans Payable

LOANS PAYABLE

NOTE E - LOANS PAYABLE

Convertible Promissory Note - Officer:

Loan Payable:

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both September 30, 2022 and 2021, the loan payable totaled $10,000.

Loans Payable - Officer:

Through September 30, 2019, J. Roy Nelson, the Company's Chief Science Officer, made net advances to the Company totaling $26,935. The loans do not bear interest and are due on demand.

In September 2018, Randall McCoy, the Company's Chief Executive Officer, advanced to the Company $4,500. The loan does not bear interest and is due on demand.

From July 2020 to September 2022, John Weber, the Company’s Chief Financial Officer, advanced to the Company a total of $90,800. The bears interest at 5% per annum and is due on demand.

XML 25 R13.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE

12 Months Ended

Sep. 30, 2022

Receivables [Abstract]

PROMISSORY NOTES PAYABLE

NOTE F – PROMISSORY NOTES PAYABLE

Bridge Financing:

XML 26 R14.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Sep. 30, 2022

RELATED PARTY TRANSACTIONS

NOTE G - RELATED PARTY TRANSACTIONS

See NoteE for loans payable to related parties.

XML 27 R15.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE H - INCOME TAXES

The Company did not incur current income tax expense for either of the years ended September 30, 2022 or 2021.

Significant components of the Company’s deferred tax assets at September 30, 2022 and 2021 are as follows:

	2022			2021
Net operating loss carry forwards	$	1,235,018		$	1,229,570
Unrealized loss		808,940			807,975
Stock based compensation		17,061			17,061
Accrued expenses		1,247,940			1,091,070
Total deferred tax assets		3,308,959			3,145,676
Valuation allowance		(3,308,959	)		(3,145,676	)
Net deferred tax assets	$	—		$	—

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

The following is a reconciliation of the Company’s income tax rate using the federal statutory rate to the actual income tax rate as of September 30, 2022 and 2021:

	2022			2021
Federal tax rate		(21	)%		(21	)%
Effect of state taxes		(6	)%		(6	)%
Effect of NOL		(2	)%		(2	)%
Change in valuation allowance		25	%		25	%
Total		0	%		0	%

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 28 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ DEFICIENCY

12 Months Ended

Sep. 30, 2022

Equity [Abstract]

STOCKHOLDERS’ DEFICIENCY

NOTE I - STOCKHOLDERS’ DEFICIENCY

Preferred Stock:

Series A

At both September 30, 2022 and 2021, 885,000 shares of Series A Preferred were outstanding.

Series B

2010 Incentive Plan:

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to the Company’s employees, officers, directors and consultants. The Plan provides for the issuance of up to 4,428,360 shares of the Company’s common stock.

No stock based compensation was recorded the years ended September 30, 2022 and 2021.

Option activity for 2022 and 2020 is summarized as follows:

	Options		Weighted Average Exercise Price
Options outstanding, October 1, 2020		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2021		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2022		11,771,334	$	0.019
Aggregate intrinsic value	$	0

The aggregate intrinsic value was calculated based on the positive difference between the closing market price of the Company’s Common Stock and the exercise price of the underlying options.

The following table summarizes information regarding stock options outstanding at September 30, 2022:

				Weighted Average Remaining				Options Exercisable Weighted Average
Ranges of prices		Number Outstanding		Contractual Life		Exercise Price		Number Exercisable		Exercise Price
$	0.020		10,000,000		1.25	$	0.020		10,000,000	$	0.020
$	0.035		1,771,344		1.25	$	0.035		1,771,344	$	0.035
	$0.020-$0.035		11,771,334		1.25	$	0.019		11,771,344	$	0.022

As of September 30, 2022, there was no unrecognized compensation cost related to non-vested options granted.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE J - SUBSEQUENT EVENTS

XML 30 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Principles of Consolidation:

Principles of Consolidation:

The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated.

Going Concern:

Going Concern:

Income (loss) per share:

Income (loss) per share:

The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares:

	2022				2021
Options		—				—

	2022		2021
Options		11,771,344		11,771,344
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		35,712,910		16,784,150
Shares excluded from the calculation of diluted loss per share		56,334,254		37,405,494

Financial Instruments and Fair Value Measurement:

Financial Instruments and Fair Value Measurement:

Use of Estimates:

Use of Estimates:

Stock-Based Compensation:

Stock-Based Compensation:

Income Taxes:

Income Taxes:

Recently Issued Accounting Pronouncements:

Recently Issued Accounting Pronouncements:

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

+ References + Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of Income per Common Share

	2022				2021
Options		—				—

Schdule of Income per Common Share Exclusuions #1

	2022		2021
Options		11,771,344		11,771,344
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		35,712,910		16,784,150
Shares excluded from the calculation of diluted loss per share		56,334,254		37,405,494

XML 32 R20.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Tables)

12 Months Ended

Sep. 30, 2022

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

	2022		2021
Professional fees	$	9,186	$	25,743
Interest		245,409		209,151
Accrued expenses	$	254,595	$	234,894

XML 33 R21.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets

	2022			2021
Net operating loss carry forwards	$	1,235,018		$	1,229,570
Unrealized loss		808,940			807,975
Stock based compensation		17,061			17,061
Accrued expenses		1,247,940			1,091,070
Total deferred tax assets		3,308,959			3,145,676
Valuation allowance		(3,308,959	)		(3,145,676	)
Net deferred tax assets	$	—		$	—

Schedule of Effective Income Tax Rate

	2022			2021
Federal tax rate		(21	)%		(21	)%
Effect of state taxes		(6	)%		(6	)%
Effect of NOL		(2	)%		(2	)%
Change in valuation allowance		25	%		25	%
Total		0	%		0	%

XML 34 R22.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ DEFICIENCY (Tables)

12 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Option Activity

	Options		Weighted Average Exercise Price
Options outstanding, October 1, 2020		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2021		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2022		11,771,334	$	0.019
Aggregate intrinsic value	$	0

Schedule of Value of Options

				Weighted Average Remaining				Options Exercisable Weighted Average
Ranges of prices		Number Outstanding		Contractual Life		Exercise Price		Number Exercisable		Exercise Price
$	0.020		10,000,000		1.25	$	0.020		10,000,000	$	0.020
$	0.035		1,771,344		1.25	$	0.035		1,771,344	$	0.035
	$0.020-$0.035		11,771,334		1.25	$	0.019		11,771,344	$	0.022

XML 35 R23.htm IDEA: XBRL DOCUMENT

THE COMPANY (Details Narrative)	12 Months Ended
THE COMPANY (Details Narrative)	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity Incorporation, Date of Incorporation	Sep. 06, 2007

XML 36 R24.htm IDEA: XBRL DOCUMENT

Schedule of Income per Common Share (Details) - USD ($)	12 Months Ended
Schedule of Income per Common Share (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Accounting Policies [Abstract]
Options

XML 37 R25.htm IDEA: XBRL DOCUMENT

Schdule of Income per Common Share Exclusuions #1 (Details) - shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Accounting Policies [Abstract]
Options	11,771,344	11,771,344
Convertible Preferred Stock	8,850,000	8,850,000
Convertible Promissory Note	35,712,910	16,784,150
Shares excluded from the calculation of diluted loss per share	56,334,254	37,405,494

XML 38 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Oct. 01, 2018
Accounting Policies [Abstract]
[custom:CumulativeEffectAdjustmentAOIC-0]				$ 950
[custom:CommonStockReceivable-0]	$ 925	$ 925	$ 2,750

XML 39 R27.htm IDEA: XBRL DOCUMENT

LICENSE OF RIGHTS (Details Narrative) - USD ($)	12 Months Ended
LICENSE OF RIGHTS (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Sale Agreement [Member]
[custom:DateOfAgreement]	Nov. 07, 2014
Sale Agreement Amended [Member]
[custom:DateOfAgreement]	Jan. 30, 2015
[custom:OptionToLicenseIPTerm]	5 years
[custom:OptionToLicenseIPCost]		$ 10,000,000

XML 40 R28.htm IDEA: XBRL DOCUMENT

Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Payables and Accruals [Abstract]
Professional fees	$ 9,186	$ 25,743
Interest	245,409	209,151
Accrued expenses	$ 254,595	$ 234,894

XML 41 R29.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE (Details Narrative) - USD ($)	12 Months Ended
LOANS PAYABLE (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Short-Term Debt [Line Items]
Loans Payable	$ 335,683
Debt Instrument, Interest Rate, Stated Percentage	500.00%
Debt Instrument, Maturity Date	Sep. 30, 2022
Loans Payable, Current	$ 10,000	$ 10,000	$ 10,000
Chief Financial Officer [Member]
Short-Term Debt [Line Items]
Loans Payable	90,800
[custom:DebtInstrumentIncurredAccruedInterestRealtedParty]	18,758	17,213
Debt Instrument, Increase, Accrued Interest	$ 65,471	$ 46,713
Chief Science Officer [Member]
Short-Term Debt [Line Items]
Loans Payable, Current				$ 26,935
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Loans Payable					$ 4,500

XML 42 R30.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
PROMISSORY NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument, Maturity Date	Sep. 30, 2022
[custom:DebtInstrumentAdditionalInterestRateStatedPercentage-0]		1000.00%
Accrued Liabilities and Other Liabilities		$ 254,595	$ 234,894
Promissory Note 2 [Member]
Debt Instrument, Issuance Date	Dec. 21, 2011
Debt Instrument, Face Amount	$ 150,000
Debt Instrument, Maturity Date	Jun. 21, 2012
[custom:BalanceOfConvertibleNotesPayable-0]	$ 175,000	175,000
Interest Expense, Debt	17,500	17,500
Accrued Liabilities and Other Liabilities	$ 179,938	$ 162,438

XML 43 R31.htm IDEA: XBRL DOCUMENT

Schedule of Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 1,235,018	$ 1,229,570
Unrealized loss	808,940	807,975
Stock based compensation	17,061	17,061
Accrued expenses	1,247,940	1,091,070
Total deferred tax assets	3,308,959	3,145,676
Valuation allowance	3,308,959	3,145,676
Net deferred tax assets

XML 44 R32.htm IDEA: XBRL DOCUMENT

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
Schedule of Effective Income Tax Rate (Details)	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Federal tax rate	(21.00%)	(21.00%)
Effect of state taxes	(6.00%)	(6.00%)
Effect of NOL	(2.00%)	(2.00%)
Change in valuation allowance	25.00%	25.00%
Total	0.00%	0.00%

XML 45 R33.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative) $ in Millions	Sep. 30, 2022 USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Operating Loss Carryforwards	$ 4.6

XML 46 R34.htm IDEA: XBRL DOCUMENT

Schedule of Option Activity (Details) - shares	Sep. 30, 2022	Sep. 30, 2021	Oct. 01, 2020
Equity [Abstract]
[custom:OptionsIssued-0]	11,771,334	11,771,334	11,771,334

XML 47 R35.htm IDEA: XBRL DOCUMENT

Schedule of Value of Options (Details) - shares	Sep. 30, 2022	Sep. 30, 2021	Oct. 01, 2020
Equity [Abstract]
[custom:OptionsIssued-0]	11,771,334	11,771,334	11,771,334

XML 48 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ DEFICIENCY (Details Narrative) - USD ($)	12 Months Ended
STOCKHOLDERS’ DEFICIENCY (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
[custom:SeriesASharesIssued-0]	885,000	885,000
[custom:CommonStockSharesAuthorizedIncentivePlan-0]	4,428,360
Common Stock, Shares, Issued	157,911,410	157,911,410
Series A Preferred Stock [Member]
Dividends Payable, Current	$ 818,030	$ 747,232
[custom:SeriesASharesIssued-0]	885,000	885,000
Series B Preferred Stock [Member]
[custom:SeriesBSharesAuthorized-0]	4,000,000
[custom:SeriesBPreferredStockLiquidationPreferenceValuePerShare-0]	$ 2.00		$ 2.00
Incentive Plan 2010 [Member]
[custom:DateOfAgreement]	Dec. 15, 2010
Board Member Options [Member]
[custom:DateOfAgreement]	Jan. 06, 2011
Common Stock, Shares, Issued	885,672
[custom:CommonStockOptionExercisePrice-0]	$ 0.035
[custom:DateOfExpirationOfOptions]	Dec. 31, 2023
Compensation Expense, Excluding Cost of Good and Service Sold	$ 1,316
Stock Option Agreement [Member]
[custom:DateOfAgreement]	Jan. 15, 2015
Common Stock, Shares, Issued	10,000,000
[custom:CommonStockOptionExercisePrice-0]	$ 0.02
[custom:DateOfExpirationOfOptions]	Dec. 31, 2023
Compensation Expense, Excluding Cost of Good and Service Sold	$ 29,508

XML 49 rgin10k_htm.xml IDEA: XBRL DOCUMENT 0001412659 2021-10-01 2022-09-30 0001412659 2022-12-31 0001412659 2021-09-30 0001412659 2020-09-30 0001412659 2022-09-30 0001412659 2020-10-01 2021-09-30 0001412659 2019-10-01 2020-09-30 0001412659 us-gaap:PreferredStockMember 2020-09-30 0001412659 us-gaap:CommonStockMember 2020-09-30 0001412659 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001412659 us-gaap:RetainedEarningsMember 2020-09-30 0001412659 us-gaap:TreasuryStockMember 2020-09-30 0001412659 us-gaap:PreferredStockMember 2020-10-01 2021-09-30 0001412659 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0001412659 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-09-30 0001412659 us-gaap:RetainedEarningsMember 2020-10-01 2021-09-30 0001412659 us-gaap:TreasuryStockMember 2020-10-01 2021-09-30 0001412659 us-gaap:PreferredStockMember 2021-09-30 0001412659 us-gaap:CommonStockMember 2021-09-30 0001412659 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001412659 us-gaap:RetainedEarningsMember 2021-09-30 0001412659 us-gaap:TreasuryStockMember 2021-09-30 0001412659 us-gaap:PreferredStockMember 2019-09-30 0001412659 us-gaap:CommonStockMember 2019-09-30 0001412659 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001412659 us-gaap:RetainedEarningsMember 2019-09-30 0001412659 us-gaap:TreasuryStockMember 2019-09-30 0001412659 2019-09-30 0001412659 us-gaap:PreferredStockMember 2019-10-01 2020-09-30 0001412659 us-gaap:CommonStockMember 2019-10-01 2020-09-30 0001412659 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2020-09-30 0001412659 us-gaap:RetainedEarningsMember 2019-10-01 2020-09-30 0001412659 us-gaap:TreasuryStockMember 2019-10-01 2020-09-30 0001412659 2018-10-01 0001412659 RGIN:SaleAgreementMember 2021-10-01 2022-09-30 0001412659 RGIN:SaleAgreementAmendedMember 2021-10-01 2022-09-30 0001412659 RGIN:SaleAgreementAmendedMember 2020-10-01 2021-09-30 0001412659 srt:ChiefFinancialOfficerMember 2021-10-01 2022-09-30 0001412659 srt:ChiefFinancialOfficerMember 2020-10-01 2021-09-30 0001412659 RGIN:ChiefScienceOfficerMember 2019-09-30 0001412659 srt:ChiefExecutiveOfficerMember 2018-09-30 0001412659 srt:ChiefFinancialOfficerMember 2022-09-30 0001412659 RGIN:PromissoryNote2Member 2021-10-01 2022-09-30 0001412659 RGIN:PromissoryNote2Member 2022-09-30 0001412659 RGIN:PromissoryNote2Member 2021-09-30 0001412659 RGIN:PromissoryNote2Member 2020-10-01 2021-09-30 0001412659 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001412659 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001412659 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001412659 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001412659 RGIN:IncentivePlan2010Member 2021-10-01 2022-09-30 0001412659 RGIN:BoardMemberOptionsMember 2021-10-01 2022-09-30 0001412659 RGIN:BoardMemberOptionsMember 2022-09-30 0001412659 RGIN:StockOptionAgreementMember 2021-10-01 2022-09-30 0001412659 RGIN:StockOptionAgreementMember 2022-09-30 0001412659 2020-10-01 iso4217:USD shares iso4217:USD shares pure 0001412659 false 2022 FY

10-K true 2022-09-30 --09-30 false 333-146834 Regenicin, Inc. WY 27-3083341 10 High Court, Little Falls, NJ 07424 973 557 8914 No No No No Non-accelerated Filer true false false 1534830 153483050

14569

1859

925 2750

15493

4609

103119

93674

65471 46713

254595

234894

4612001

4031001

175000

335683

10000

122235

82235

5612633

4962487

0.001 0.001 5500000 5500000 885000 885000 885 885

0.001

200000000

157911410

153483050

157914

10208339

15959850

15320588

4428360

4428

-5597140

-4957878

15493

4609

601179

635864

601179

635864

18758

17213

-36258

-34713

1825

38083

34738

-639262

-670602

52954

70405

-692216

-741007

-0.00

153483050

885000

885

157911410

157914

10208339

-15320588

-4428

-4957878

-639262

885

157914

10208339

-15959850

-4428

-5597140

885

157914

10208339

-14649986

-4428

-4287276

-670602

885

157914

10208339

-15320588

-4428

-4957878

-639262

-670602

1825

-36258

-34713

9443

5015

-16555

25743

581000

580999

-27291

-24107

40000

24600

40000

24600

12709

493

1859

1366

14568

1859

NOTE A - THE COMPANY Regenicin, Inc. ("Regenicin"), formerly known as Windstar, Inc., was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. On August 31, 2022, we filed articles of continuance with the states of Nevada and Wyoming effectively moving our organizational jurisdiction from Nevada to Wyoming effective on that date. The Company's business plan is to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

2007-09-06

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation: The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated. Going Concern: The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of September 30, 2022, has an accumulated deficit of approximately $15.95 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Income (loss) per share: Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive. The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares: <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBQzKgMmM40g" style="margin-left: auto; width: 40%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - Schedule of Income per Common Share (Details)"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td colspan="3" id="xdx_492_20201001__20210930_zeyGiVCxwiB7" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2022</td> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_498_20191001__20200930_z4xC1BvgxEQf" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2021</td> <td style="font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zo0NGoXtS238" style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; width: 54%; background-color: #CCEECC; padding-bottom: 1pt">Options</td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%"> </td></tr> </table> The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net losses incurred during 2022 and 2021: <table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock_zPtkmVLtwFNi" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_492_20201001__20210930_z5SlOmg9YX5l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_492_20191001__20200930_zDt1xXO3bFNj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_40C_ecustom--OptionIssuableUponConversionAndExercise_zGgCNOY5ijx" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt">Options</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertiblePreferredStockIssuableUponConversionAndExercise_zAm7NAkLeQp6" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Convertible Preferred Stock</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ConvertiblePromissoryNoteIssuable_zaf0DUXg4k2b" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible Promissory Note</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35,712,910</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,784,150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z2i8PAdDuize" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares excluded from the calculation of diluted loss per share</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56,334,254</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,405,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> </table> Financial Instruments and Fair Value Measurement: As of October 1, 2018, the Company adopted ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There no longer is an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. As a result of the adoption, the Company recorded a cumulative effect adjustment of a $950 decrease to accumulated other comprehensive income, and a corresponding decrease to accumulated deficit, as of October 1, 2018. Common stock of Amarantus BioScience Holdings, Inc. ("Amarantus") is carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, and unrealized gains and losses are included in other income (expense) on the statement of operations. The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at September 30, 2022 is $925. The change in unrealized loss for the year ended September 30, 2022 and 2021 was $1,825 and $25 net of income taxes, respectively, and was reported as other expense. The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of and September 30, 2022 and 2021 due to their short-term nature. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimation includes the selection of assumptions underlying the calculation of the fair value of options. Actual results could differ from those estimates. Stock-Based Compensation: The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option pricing model. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505. Income Taxes: The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, "Income Taxes," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. The Company has adopted the provisions of FASB ASC 740-10-05 "Accounting for Uncertainty in Income Taxes." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Recently Issued Accounting Pronouncements: Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

Principles of Consolidation: The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated.

Going Concern: The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of September 30, 2022, has an accumulated deficit of approximately $15.95 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Income (loss) per share: Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive. The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares: <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBQzKgMmM40g" style="margin-left: auto; width: 40%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - Schedule of Income per Common Share (Details)"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td colspan="3" id="xdx_492_20201001__20210930_zeyGiVCxwiB7" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2022</td> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_498_20191001__20200930_z4xC1BvgxEQf" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2021</td> <td style="font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zo0NGoXtS238" style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; width: 54%; background-color: #CCEECC; padding-bottom: 1pt">Options</td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%"> </td></tr> </table> The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net losses incurred during 2022 and 2021: <table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock_zPtkmVLtwFNi" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_492_20201001__20210930_z5SlOmg9YX5l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_492_20191001__20200930_zDt1xXO3bFNj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_40C_ecustom--OptionIssuableUponConversionAndExercise_zGgCNOY5ijx" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt">Options</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertiblePreferredStockIssuableUponConversionAndExercise_zAm7NAkLeQp6" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Convertible Preferred Stock</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ConvertiblePromissoryNoteIssuable_zaf0DUXg4k2b" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible Promissory Note</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35,712,910</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,784,150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z2i8PAdDuize" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares excluded from the calculation of diluted loss per share</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56,334,254</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,405,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBQzKgMmM40g" style="margin-left: auto; width: 40%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - Schedule of Income per Common Share (Details)"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td colspan="3" id="xdx_492_20201001__20210930_zeyGiVCxwiB7" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2022</td> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_498_20191001__20200930_z4xC1BvgxEQf" style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2021</td> <td style="font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zo0NGoXtS238" style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; width: 54%; background-color: #CCEECC; padding-bottom: 1pt">Options</td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC"> </td> <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 20%; background-color: #CCEECC; text-align: right">— </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEECC; padding-bottom: 1pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 1%"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock_zPtkmVLtwFNi" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_492_20201001__20210930_z5SlOmg9YX5l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_492_20191001__20200930_zDt1xXO3bFNj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_40C_ecustom--OptionIssuableUponConversionAndExercise_zGgCNOY5ijx" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt">Options</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 20%; font-size: 10pt; text-align: right">11,771,344</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertiblePreferredStockIssuableUponConversionAndExercise_zAm7NAkLeQp6" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Convertible Preferred Stock</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,850,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ConvertiblePromissoryNoteIssuable_zaf0DUXg4k2b" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible Promissory Note</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35,712,910</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,784,150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z2i8PAdDuize" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares excluded from the calculation of diluted loss per share</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56,334,254</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,405,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> </table> 11771344 11771344 8850000 8850000 35712910 16784150

56334254

37405494

Financial Instruments and Fair Value Measurement: As of October 1, 2018, the Company adopted ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There no longer is an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. As a result of the adoption, the Company recorded a cumulative effect adjustment of a $950 decrease to accumulated other comprehensive income, and a corresponding decrease to accumulated deficit, as of October 1, 2018. Common stock of Amarantus BioScience Holdings, Inc. ("Amarantus") is carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, and unrealized gains and losses are included in other income (expense) on the statement of operations. The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at September 30, 2022 is $925. The change in unrealized loss for the year ended September 30, 2022 and 2021 was $1,825 and $25 net of income taxes, respectively, and was reported as other expense. The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of and September 30, 2022 and 2021 due to their short-term nature.

950 925

Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimation includes the selection of assumptions underlying the calculation of the fair value of options. Actual results could differ from those estimates.

Stock-Based Compensation: The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option pricing model. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505.

Income Taxes: The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, "Income Taxes," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. The Company has adopted the provisions of FASB ASC 740-10-05 "Accounting for Uncertainty in Income Taxes." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

Recently Issued Accounting Pronouncements: Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

NOTE C – LICENSE OF RIGHTS On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus BioScience Holdings, Inc. (“Amarantus”). Under the Sale Agreement, the Company granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus could exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. The option had not been exercised and had since expired. 2014-11-07 2015-01-30 P5Y 10000000

NOTE D – ACCRUED EXPENSES Accrued expenses consisted of the following: <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQ4JMmRWNbfb" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_499_20210930_zUznCU39Ss1a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20200930_zXaI4jemjKT2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_zSaN6kCsljyi" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt; text-align: left; padding-left: 5.5pt">Professional fees</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">9,186</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">25,743</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_zYGr49fbkZH8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.5pt">Interest</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">245,409</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">209,151</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_zv8yvlM0NQS4" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="padding-left: 5.5pt; padding-bottom: 2.5pt">Accrued expenses</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">254,595</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">234,894</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQ4JMmRWNbfb" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_499_20210930_zUznCU39Ss1a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20200930_zXaI4jemjKT2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_zSaN6kCsljyi" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt; text-align: left; padding-left: 5.5pt">Professional fees</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">9,186</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">25,743</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_zYGr49fbkZH8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.5pt">Interest</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">245,409</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">209,151</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_zv8yvlM0NQS4" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="padding-left: 5.5pt; padding-bottom: 2.5pt">Accrued expenses</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">254,595</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">234,894</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>

9186

25743

245409

209151

254595

234894

NOTE E - LOANS PAYABLE Convertible Promissory Note - Officer: Through March 31, 2020, John Weber, the Company's Chief Financial Officer, advanced the Company a total of $335,683. On March 31, 2020, these advances were converted into a convertible promissory note. Interest on the note is computed at 5% per annum and accrues from the time of the advances until the maturity date. The original maturity date was September 30, 2020, at which time all the accrued interest and principal became due. The note has been extended several times and most recently to September 30, 2022. For the years ended September 30, 2022 and 2021 interest totaling $18,758 and $17,213 respectively was incurred and accrued. Lifetime accrued interest on the note was $65,471 and $46,713 at September 30, 2022 and 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets The note is convertible at the option of Mr. Weber into shares of the Company's common stock at the prevailing market rate on the date of conversion. Loan Payable: In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both September 30, 2022 and 2021, the loan payable totaled $10,000. Loans Payable - Officer: Through September 30, 2019, J. Roy Nelson, the Company's Chief Science Officer, made net advances to the Company totaling $26,935. The loans do not bear interest and are due on demand. In September 2018, Randall McCoy, the Company's Chief Executive Officer, advanced to the Company $4,500. The loan does not bear interest and is due on demand. From July 2020 to September 2022, John Weber, the Company’s Chief Financial Officer, advanced to the Company a total of $90,800. The bears interest at 5% per annum and is due on demand.

335683

2022-09-30

18758 17213

65471

46713

10000

26935

4500

90800

NOTE F – PROMISSORY NOTES PAYABLE Bridge Financing: On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both September 30, 2022 and 2021, the note balance was $175,000. Interest expense was $17,500 for each of the years ended September 30, 2022, and 2021, respectively. Accrued interest on the note was $179,938 and $162,438 at September 30, 2022 and 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets.

2011-12-21

150000

2012-06-21

10 175000 175000

17500

179938

162438

NOTE G - RELATED PARTY TRANSACTIONS The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities. The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An officer of the Company is an owner of CPR. No rent is charged for either premise. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR. See NoteE for loans payable to related parties.

NOTE H - INCOME TAXES The Company did not incur current income tax expense for either of the years ended September 30, 2022 or 2021. At September 30, 2022, the Company had available approximately $4.6 million of net operating loss (“NOL”) carry forwards which expire in the years 2029 through 2037. However, the use of the net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code. The Company has not yet undertaken the process to calculate these changes. Significant components of the Company’s deferred tax assets at September 30, 2022 and 2021 are as follows: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLjBCMCxvob5" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Deferred Tax Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_493_20210930_ztZrXW5Renoc" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20200930_zTmWkdrhEnld" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_zqE9JptG7HX1" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt; text-align: left">Net operating loss carry forwards</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">1,235,018</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">1,229,570</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--UnrealizedCapitalLossOnAvailableForSaleSecurities_i01I_zHpqFFj3rora" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unrealized loss</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">808,940</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">807,975</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsStockBasedCompensation_i01I_pp0p0_zy5yMOrTTHE4" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left">Stock based compensation</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">17,061</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">17,061</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsAccruedExpenses_i01I_pp0p0_zwigDHf0P2K3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued expenses</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,247,940</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,091,070</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_i01TIC_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,308,959</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,145,676</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,308,959</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,145,676</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_i01TIC_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">— </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">— </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets. The following is a reconciliation of the Company’s income tax rate using the federal statutory rate to the actual income tax rate as of September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zRUhXQ2U0f0b" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Effective Income Tax Rate (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td colspan="3" id="xdx_49A_20201001__20210930_zHKgSZYqzxH3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20191001__20200930_zUQRFVAlzKzd" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; text-align: left">Federal tax rate</td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of state taxes</td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateEffectOfNOL_iI_zCL71eYz0409" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td>Effect of NOL</td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="padding-bottom: 2.5pt">Total</td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> At September 30, 2022 and 2021, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of September 30, 2022, and 2021 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions. The Company files its federal and state income tax returns under a statute of limitations. The tax years ended September 30, 2020 through September 30, 2022 generally remain subject to examination by federal tax authorities.

4600000

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLjBCMCxvob5" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Deferred Tax Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" id="xdx_493_20210930_ztZrXW5Renoc" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20200930_zTmWkdrhEnld" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_zqE9JptG7HX1" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-size: 10pt; text-align: left">Net operating loss carry forwards</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">1,235,018</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">1,229,570</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--UnrealizedCapitalLossOnAvailableForSaleSecurities_i01I_zHpqFFj3rora" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unrealized loss</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">808,940</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">807,975</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsStockBasedCompensation_i01I_pp0p0_zy5yMOrTTHE4" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left">Stock based compensation</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">17,061</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">17,061</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsAccruedExpenses_i01I_pp0p0_zwigDHf0P2K3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued expenses</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,247,940</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,091,070</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_i01TIC_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,308,959</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,145,676</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,308,959</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,145,676</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_i01TIC_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">— </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">— </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>

1235018

1229570

808940 807975 17061 17061 1247940 1091070

3308959

3145676

-3308959

-3145676

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zRUhXQ2U0f0b" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - Schedule of Effective Income Tax Rate (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td colspan="3" id="xdx_49A_20201001__20210930_zHKgSZYqzxH3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20191001__20200930_zUQRFVAlzKzd" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; text-align: left">Federal tax rate</td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of state taxes</td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateEffectOfNOL_iI_zCL71eYz0409" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td>Effect of NOL</td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="padding-bottom: 2.5pt">Total</td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-0.21

-0.06

-0.02 -0.02

0.25

NOTE I - STOCKHOLDERS’ DEFICIENCY Preferred Stock: Series A Series A Preferred earns a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of September 30, 2022 and 2021 plus dividends in arrears as per below). Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1. The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three-year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. There have been no new developments related to the remaining Series A holders regarding this claim and the conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit. The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of September 30, 2022, and 2021, dividends in arrears were $818,030 ($.92 per share) and $747,232 ($.84 per share), respectively. At both September 30, 2022 and 2021, 885,000 shares of Series A Preferred were outstanding. Series B On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). 4,000,000 shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Preferred have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At September 30, 2021, and 2020 no shares of Series B Preferred are outstanding. 2010 Incentive Plan: On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to the Company’s employees, officers, directors and consultants. The Plan provides for the issuance of up to 4,428,360 shares of the Company’s common stock. Effective October 1, 2019, the Company adopted ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The adoption of ASU 2018-07 did not have a significant impact on the Company’s consolidated financial statements. On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire, as extended, on December 31, 2018. Effective as of the expiration date, the Company extended the term of those options for two of the directors to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company's shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $1,316 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.035, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years. On January 15, 2015, the Company approved the issuance of 10,000,000 options to one of its Officers at an exercise price of $0.02, per share that were set to expire on January 15, 2019. Effective December 31, 2019, the Company extended the term of those options to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $29,508 in compensation expense, which is included in the results of operations for the year ended September 30, 2021. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.02, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company’s common stock as the Company’s common stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued. No stock based compensation was recorded the years ended September 30, 2022 and 2021. Option activity for 2022 and 2020 is summarized as follows: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXbQFbLLdp3f" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of Option Activity (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 50%; font-size: 10pt; text-align: right">Options outstanding, October 1, 2020</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--OptionsIssued_iI_c20201001_zhlAP5qdIaW9" style="width: 20%; font-size: 10pt; text-align: right">11,771,334</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">0.019</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Granted</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Forfeited</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Options outstanding, September 30, 2021</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_ecustom--OptionsIssued_iI_c20210930_zIxojNdaDsx7" style="font-size: 10pt; text-align: right">11,771,334</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.019</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Granted</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Forfeited</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Options outstanding, September 30, 2022</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_ecustom--OptionsIssued_iI_c20220930_zETFFOPBAgn" style="font-size: 10pt; text-align: right">11,771,334</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.019</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Aggregate intrinsic value</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value was calculated based on the positive difference between the closing market price of the Company’s Common Stock and the exercise price of the underlying options. The following table summarizes information regarding stock options outstanding at September 30, 2022: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfWxB9ZHXIb1" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - Schedule of Value of Options (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining</td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">Options Exercisable Weighted Average</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1pt solid">Ranges of prices</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Contractual Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">1.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.020</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,771,344</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">1.25</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,771,344</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">$0.020-$0.035</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_ecustom--OptionsIssued_iI_c20220930_zhs6FRxqddG1" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right">11,771,334</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center">1.25</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.019</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">11,771,344</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.022</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> As of September 30, 2022, there was no unrecognized compensation cost related to non-vested options granted.

818030

747232

885000 885000 4000000 2.00 2.00 2010-12-15 4428360 2011-01-06

885672

0.035 2023-12-31

1316

2015-01-15

10000000

0.02 2023-12-31

29508

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXbQFbLLdp3f" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of Option Activity (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 50%; font-size: 10pt; text-align: right">Options outstanding, October 1, 2020</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--OptionsIssued_iI_c20201001_zhlAP5qdIaW9" style="width: 20%; font-size: 10pt; text-align: right">11,771,334</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 20%; font-size: 10pt; text-align: right">0.019</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Granted</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Forfeited</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Options outstanding, September 30, 2021</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_ecustom--OptionsIssued_iI_c20210930_zIxojNdaDsx7" style="font-size: 10pt; text-align: right">11,771,334</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.019</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Granted</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Forfeited</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">— </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Options outstanding, September 30, 2022</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_ecustom--OptionsIssued_iI_c20220930_zETFFOPBAgn" style="font-size: 10pt; text-align: right">11,771,334</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.019</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">Aggregate intrinsic value</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

11771334 11771334 11771334

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfWxB9ZHXIb1" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - Schedule of Value of Options (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining</td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">Options Exercisable Weighted Average</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1pt solid">Ranges of prices</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Contractual Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">1.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.020</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,771,344</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">1.25</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,771,344</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.035</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">$0.020-$0.035</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_ecustom--OptionsIssued_iI_c20220930_zhs6FRxqddG1" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right">11,771,334</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center">1.25</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.019</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">11,771,344</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.022</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

11771334

NOTE J - SUBSEQUENT EVENTS Subsequent to the end of this fiscal year, in October 2022, we set up a new Nevada Series LLC called NovaDerm Product Package, LLC (“NPP LLC”). During November and December 2022, consistent with Nevada law governing this Master Series LLC, we then establish twenty-five (25) individual series LLCs, identifying each with a series letter of A through T or AA through EE. Thus, each of these sub-entities were named NovaDerm Product Package Series A, LLC through Series T, LLC, and then Series AA to Series EE, LLC (or NPP-A through NPP-T and NPP-AA through NPP-EE for short). Into each of these twenty-five individual Series LLCs, we contributed the right and exclusive ownership to a certain amount of the bovine hides and corium we currently own and use as key materials in the preparation of our NovaDerm® product, as well as the right to designate: (a) the specific patient cultured skin to be prepared from these materials; (b) the amount of this cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC we designated 33,333 cm2 of these NovaDerm® Product Rights. For NPP-DD we designated 30,625 cm2 of NovaDerm® Product Rights and for NPP-EE we designated 28,783 cm2 of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued. We subsequently transferred 99% of our membership interests (or 99 membership interests) in each of these Series LLC to various Limited Liability Companies, held by individuals unknown to us, in exchange for a pre-agreed payment. Prior to year-end, the members of these LLCs voted to donate 100% of the membership interests to charity. While we retain possession of the materials transferred in each Series LLC contribution, we have a continuing obligation to segregated and manage those materials as well as to prepare the NovaDerm® cultured skin product as designated by each Series LLC holder or their designate. The identified materials are currently set apart from other such materials and are being held by us pending the identification of the patient and medical facility as instructed by each NovaDerm® Product Rights holder. Notwithstanding this retention of possession by us, the ownership and legal title to the materials are retained and fully vested in the individual Series LLC or its designate. The above-described transfers of membership interests in the Series LLCs generated a substantial amount of cash which we are obligated to use for the completion of our NovaDerm IND and the administration of our product clinical trials. No assurance, however, can be given as to the success or failure of such IND or clinical trials, or as to any future FDA decisions made following these trials.

N/A 9999 N/A

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ʨ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 56 155 1 false 16 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://RGIN/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://RGIN/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://RGIN/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://RGIN/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://RGIN/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY Sheet http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://RGIN/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - THE COMPANY Sheet http://RGIN/role/Company THE COMPANY Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://RGIN/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - LICENSE OF RIGHTS Sheet http://RGIN/role/LicenseOfRights LICENSE OF RIGHTS Notes 10 false false R11.htm 00000011 - Disclosure - ACCRUED EXPENSES Sheet http://RGIN/role/AccruedExpenses ACCRUED EXPENSES Notes 11 false false R12.htm 00000012 - Disclosure - LOANS PAYABLE Sheet http://RGIN/role/LoansPayable LOANS PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - PROMISSORY NOTES PAYABLE Notes http://RGIN/role/PromissoryNotesPayable PROMISSORY NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://RGIN/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 00000015 - Disclosure - INCOME TAXES Sheet http://RGIN/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 00000016 - Disclosure - STOCKHOLDERS??? DEFICIENCY Sheet http://RGIN/role/StockholdersDeficiency STOCKHOLDERS??? DEFICIENCY Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://RGIN/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://RGIN/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://RGIN/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://RGIN/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://RGIN/role/AccruedExpenses 20 false false R21.htm 00000021 - Disclosure - INCOME TAXES (Tables) Sheet http://RGIN/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://RGIN/role/IncomeTaxes 21 false false R22.htm 00000022 - Disclosure - STOCKHOLDERS??? DEFICIENCY (Tables) Sheet http://RGIN/role/StockholdersDeficiencyTables STOCKHOLDERS??? DEFICIENCY (Tables) Tables http://RGIN/role/StockholdersDeficiency 22 false false R23.htm 00000023 - Disclosure - THE COMPANY (Details Narrative) Sheet http://RGIN/role/CompanyDetailsNarrative THE COMPANY (Details Narrative) Details http://RGIN/role/Company 23 false false R24.htm 00000024 - Disclosure - Schedule of Income per Common Share (Details) Sheet http://RGIN/role/ScheduleOfIncomePerCommonShareDetails Schedule of Income per Common Share (Details) Details 24 false false R25.htm 00000025 - Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details) Sheet http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details Schdule of Income per Common Share Exclusuions #1 (Details) Details 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://RGIN/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://RGIN/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - LICENSE OF RIGHTS (Details Narrative) Sheet http://RGIN/role/LicenseOfRightsDetailsNarrative LICENSE OF RIGHTS (Details Narrative) Details http://RGIN/role/LicenseOfRights 27 false false R28.htm 00000028 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://RGIN/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 28 false false R29.htm 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://RGIN/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://RGIN/role/LoansPayable 29 false false R30.htm 00000030 - Disclosure - PROMISSORY NOTES PAYABLE (Details Narrative) Notes http://RGIN/role/PromissoryNotesPayableDetailsNarrative PROMISSORY NOTES PAYABLE (Details Narrative) Details http://RGIN/role/PromissoryNotesPayable 30 false false R31.htm 00000031 - Disclosure - Schedule of Deferred Tax Assets (Details) Sheet http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails Schedule of Deferred Tax Assets (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Effective Income Tax Rate (Details) Sheet http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails Schedule of Effective Income Tax Rate (Details) Details 32 false false R33.htm 00000033 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://RGIN/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://RGIN/role/IncomeTaxesTables 33 false false R34.htm 00000034 - Disclosure - Schedule of Option Activity (Details) Sheet http://RGIN/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Value of Options (Details) Sheet http://RGIN/role/ScheduleOfValueOfOptionsDetails Schedule of Value of Options (Details) Details 35 false false R36.htm 00000036 - Disclosure - STOCKHOLDERS??? DEFICIENCY (Details Narrative) Sheet http://RGIN/role/StockholdersDeficiencyDetailsNarrative STOCKHOLDERS??? DEFICIENCY (Details Narrative) Details http://RGIN/role/StockholdersDeficiencyTables 36 false false All Reports Book All Reports [dqc-0015-Negative-Values] Fact us-gaap:InterestExpense has a value of -36258 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:InterestExpense fact are: Context: From2020-10-012021-09-30, Unit: USD, Rule Element Id: 1367. rgin10k.htm 2082 [dqc-0015-Negative-Values] Fact us-gaap:InterestExpense has a value of -34713 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:InterestExpense fact are: Context: From2019-10-012020-09-30, Unit: USD, Rule Element Id: 1367. rgin10k.htm 2083 [dqc-0015-Negative-Values] Fact us-gaap:DeferredTaxAssetsValuationAllowance has a value of -3308959 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DeferredTaxAssetsValuationAllowance fact are: Context: AsOf2021-09-30, Unit: USD, Rule Element Id: 633. rgin10k.htm 2903 [dqc-0015-Negative-Values] Fact us-gaap:DeferredTaxAssetsValuationAllowance has a value of -3145676 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DeferredTaxAssetsValuationAllowance fact are: Context: AsOf2020-09-30, Unit: USD, Rule Element Id: 633. rgin10k.htm 2904 rgin10k.htm ex31_1.htm ex31_2.htm ex32_1.htm ex3_3.htm rgin-20220930.xsd rgin-20220930_cal.xml rgin-20220930_def.xml rgin-20220930_lab.xml rgin-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rgin10k.htm": { "axisCustom": 3, "axisStandard": 2, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 208, "http://xbrl.sec.gov/dei/2022": 33 }, "contextCount": 56, "dts": { "calculationLink": { "local": [ "rgin-20220930_cal.xml" ] }, "definitionLink": { "local": [ "rgin-20220930_def.xml" ] }, "inline": { "local": [ "rgin10k.htm" ] }, "labelLink": { "local": [ "rgin-20220930_lab.xml" ] }, "presentationLink": { "local": [ "rgin-20220930_pre.xml" ] }, "schema": { "local": [ "rgin-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 240, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 18, "http://xbrl.sec.gov/dei/2022": 4, "total": 22 }, "keyCustom": 29, "keyStandard": 126, "memberCustom": 7, "memberStandard": 9, "nsprefix": "RGIN", "nsuri": "http://RGIN/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://RGIN/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:SaleOfAssetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - LICENSE OF RIGHTS", "menuCat": "Notes", "order": "10", "role": "http://RGIN/role/LicenseOfRights", "shortName": "LICENSE OF RIGHTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:SaleOfAssetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACCRUED EXPENSES", "menuCat": "Notes", "order": "11", "role": "http://RGIN/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - LOANS PAYABLE", "menuCat": "Notes", "order": "12", "role": "http://RGIN/role/LoansPayable", "shortName": "LOANS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - PROMISSORY NOTES PAYABLE", "menuCat": "Notes", "order": "13", "role": "http://RGIN/role/PromissoryNotesPayable", "shortName": "PROMISSORY NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "14", "role": "http://RGIN/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "15", "role": "http://RGIN/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY", "menuCat": "Notes", "order": "16", "role": "http://RGIN/role/StockholdersDeficiency", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "17", "role": "http://RGIN/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "18", "role": "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://RGIN/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://RGIN/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://RGIN/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "21", "role": "http://RGIN/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY (Tables)", "menuCat": "Tables", "order": "22", "role": "http://RGIN/role/StockholdersDeficiencyTables", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - THE COMPANY (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://RGIN/role/CompanyDetailsNarrative", "shortName": "THE COMPANY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Schedule of Income per Common Share (Details)", "menuCat": "Details", "order": "24", "role": "http://RGIN/role/ScheduleOfIncomePerCommonShareDetails", "shortName": "Schedule of Income per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "RGIN:ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "RGIN:OptionIssuableUponConversionAndExercise", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schdule of Income per Common Share Exclusuions #1 (Details)", "menuCat": "Details", "order": "25", "role": "http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details", "shortName": "Schdule of Income per Common Share Exclusuions #1 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "RGIN:ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "RGIN:OptionIssuableUponConversionAndExercise", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2018-10-01", "decimals": "0", "first": true, "lang": null, "name": "RGIN:CumulativeEffectAdjustmentAOIC", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://RGIN/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2018-10-01", "decimals": "0", "first": true, "lang": null, "name": "RGIN:CumulativeEffectAdjustmentAOIC", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "RGIN:SaleOfAssetTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-012022-09-30_custom_SaleAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:DateOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - LICENSE OF RIGHTS (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://RGIN/role/LicenseOfRightsDetailsNarrative", "shortName": "LICENSE OF RIGHTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "RGIN:SaleOfAssetTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-012022-09-30_custom_SaleAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "RGIN:DateOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Accrued Expenses (Details)", "menuCat": "Details", "order": "28", "role": "http://RGIN/role/ScheduleOfAccruedExpensesDetails", "shortName": "Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "RGIN:LoansPayableTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LOANS PAYABLE (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://RGIN/role/LoansPayableDetailsNarrative", "shortName": "LOANS PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "RGIN:LoansPayableTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "RGIN:AccruedLiabilitiesCurrentRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "RGIN:AccruedLiabilitiesCurrentRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "RGIN:LoansPayableTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - PROMISSORY NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://RGIN/role/PromissoryNotesPayableDetailsNarrative", "shortName": "PROMISSORY NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "lang": null, "name": "RGIN:DebtInstrumentAdditionalInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Percent", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Deferred Tax Assets (Details)", "menuCat": "Details", "order": "31", "role": "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "Schedule of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percent", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Effective Income Tax Rate (Details)", "menuCat": "Details", "order": "32", "role": "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails", "shortName": "Schedule of Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percent", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://RGIN/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "RGIN:OptionsIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Option Activity (Details)", "menuCat": "Details", "order": "34", "role": "http://RGIN/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "RGIN:OptionsIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Value of Options (Details)", "menuCat": "Details", "order": "35", "role": "http://RGIN/role/ScheduleOfValueOfOptionsDetails", "shortName": "Schedule of Value of Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "RGIN:SeriesASharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://RGIN/role/StockholdersDeficiencyDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "lang": null, "name": "RGIN:CommonStockSharesAuthorizedIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://RGIN/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://RGIN/role/ConsolidatedStatementsOfOperationsParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY", "menuCat": "Statements", "order": "6", "role": "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIENCY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "AsOf2019-09-30", "decimals": "0", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://RGIN/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2020-10-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInInterestPayableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - THE COMPANY", "menuCat": "Notes", "order": "8", "role": "http://RGIN/role/Company", "shortName": "THE COMPANY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://RGIN/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rgin10k.htm", "contextRef": "From2021-10-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 16, "tag": { "RGIN_AccruedLiabilitiesCurrentRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:AccruedLiabilitiesCurrentRelatedParties-0]" } } }, "localname": "AccruedLiabilitiesCurrentRelatedParties", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "RGIN_BalanceOfConvertibleNotesPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:BalanceOfConvertibleNotesPayable-0]" } } }, "localname": "BalanceOfConvertibleNotesPayable", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGIN_BoardMemberOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Member Options [Member]" } } }, "localname": "BoardMemberOptionsMember", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_ChiefScienceOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Science Officer [Member]" } } }, "localname": "ChiefScienceOfficerMember", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_CommonStockOptionExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CommonStockOptionExercisePrice-0]" } } }, "localname": "CommonStockOptionExercisePrice", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "RGIN_CommonStockReceivable": { "auth_ref": [], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Common stock of Amarantus", "verboseLabel": "[custom:CommonStockReceivable-0]" } } }, "localname": "CommonStockReceivable", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets", "http://RGIN/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGIN_CommonStockSharesAuthorizedIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CommonStockSharesAuthorizedIncentivePlan-0]" } } }, "localname": "CommonStockSharesAuthorizedIncentivePlan", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RGIN_ConvertiblePreferredStockIssuableUponConversionAndExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockIssuableUponConversionAndExercise", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details" ], "xbrltype": "sharesItemType" }, "RGIN_ConvertiblePromissoryNoteIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note" } } }, "localname": "ConvertiblePromissoryNoteIssuable", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details" ], "xbrltype": "sharesItemType" }, "RGIN_CumulativeEffectAdjustmentAOIC": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CumulativeEffectAdjustmentAOIC-0]" } } }, "localname": "CumulativeEffectAdjustmentAOIC", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGIN_DateOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DateOfAgreement]" } } }, "localname": "DateOfAgreement", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative", "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "dateItemType" }, "RGIN_DateOfExpirationOfOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DateOfExpirationOfOptions]" } } }, "localname": "DateOfExpirationOfOptions", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "dateItemType" }, "RGIN_DebtInstrumentAdditionalInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DebtInstrumentAdditionalInterestRateStatedPercentage-0]" } } }, "localname": "DebtInstrumentAdditionalInterestRateStatedPercentage", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "RGIN_DebtInstrumentIncurredAccruedInterestRealtedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DebtInstrumentIncurredAccruedInterestRealtedParty]" } } }, "localname": "DebtInstrumentIncurredAccruedInterestRealtedParty", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGIN_DeferredTaxAssetsAccruedExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsAccruedExpenses", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "RGIN_DeferredTaxAssetsStockBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsStockBasedCompensation", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "RGIN_DisclosureLicenseOfRightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Of Rights" } } }, "localname": "DisclosureLicenseOfRightsAbstract", "nsuri": "http://RGIN/20220930", "xbrltype": "stringItemType" }, "RGIN_DisclosureLoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable" } } }, "localname": "DisclosureLoansPayableAbstract", "nsuri": "http://RGIN/20220930", "xbrltype": "stringItemType" }, "RGIN_EffectiveIncomeTaxRateEffectOfNOL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect of NOL" } } }, "localname": "EffectiveIncomeTaxRateEffectOfNOL", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "RGIN_IncentivePlan2010Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Plan 2010 [Member]" } } }, "localname": "IncentivePlan2010Member", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_LoansPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOANS PAYABLE" } } }, "localname": "LoansPayableTextBlock", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "RGIN_NotesPayableAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable [Axis]", "verboseLabel": "NotesPayableAxis [Axis]" } } }, "localname": "NotesPayableAxis", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "RGIN_NotesPayableDomain": { "auth_ref": [], "localname": "NotesPayableDomain", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_OptionIssuableUponConversionAndExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OptionIssuableUponConversionAndExercise", "verboseLabel": "Options" } } }, "localname": "OptionIssuableUponConversionAndExercise", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details" ], "xbrltype": "sharesItemType" }, "RGIN_OptionToLicenseIPCost": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:OptionToLicenseIPCost]" } } }, "localname": "OptionToLicenseIPCost", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGIN_OptionToLicenseIPTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:OptionToLicenseIPTerm]" } } }, "localname": "OptionToLicenseIPTerm", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "durationItemType" }, "RGIN_OptionsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:OptionsIssued-0]" } } }, "localname": "OptionsIssued", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ScheduleOfOptionActivityDetails", "http://RGIN/role/ScheduleOfValueOfOptionsDetails" ], "xbrltype": "sharesItemType" }, "RGIN_PromissoryNote2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note 2 [Member]" } } }, "localname": "PromissoryNote2Member", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_SaleAgreementAmendedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale Agreement Amended [Member]" } } }, "localname": "SaleAgreementAmendedMember", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_SaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale Agreement [Member]" } } }, "localname": "SaleAgreementMember", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_SaleOfAssetTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE OF RIGHTS" } } }, "localname": "SaleOfAssetTextBlock", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRights" ], "xbrltype": "textBlockItemType" }, "RGIN_SaleOfAssetsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale Of Assets [Axis]", "verboseLabel": "SaleOfAssetsAxis [Axis]" } } }, "localname": "SaleOfAssetsAxis", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "stringItemType" }, "RGIN_SaleOfAssetsDomain": { "auth_ref": [], "localname": "SaleOfAssetsDomain", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/LicenseOfRightsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schdule of Income per Common Share Exclusuions #1" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedExcludedSecuritiesTableTextBlock", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "RGIN_SeriesAPreferredStockAtParValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SeriesAPreferredStockAtParValue-0]" } } }, "localname": "SeriesAPreferredStockAtParValue", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "RGIN_SeriesAPreferredStockValue": { "auth_ref": [], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding" } } }, "localname": "SeriesAPreferredStockValue", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "perShareItemType" }, "RGIN_SeriesASharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SeriesASharesAuthorized-0]" } } }, "localname": "SeriesASharesAuthorized", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "RGIN_SeriesASharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SeriesASharesIssued-0]" } } }, "localname": "SeriesASharesIssued", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical", "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RGIN_SeriesBPreferredStockLiquidationPreferenceValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SeriesBPreferredStockLiquidationPreferenceValuePerShare-0]" } } }, "localname": "SeriesBPreferredStockLiquidationPreferenceValuePerShare", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "RGIN_SeriesBSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SeriesBSharesAuthorized-0]" } } }, "localname": "SeriesBSharesAuthorized", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RGIN_StatementEquityComponentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Equity Component [Axis]", "verboseLabel": "StatementEquityComponentAxis [Axis]" } } }, "localname": "StatementEquityComponentAxis", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "RGIN_StatementEquityComponentDomain": { "auth_ref": [], "localname": "StatementEquityComponentDomain", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_StockOptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Agreement [Member]" } } }, "localname": "StockOptionAgreementMember", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGIN_UnrealizedCapitalLossOnAvailableForSaleSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrealized loss" } } }, "localname": "UnrealizedCapitalLossOnAvailableForSaleSecurities", "nsuri": "http://RGIN/20220930", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r270", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r270", "r272", "r273" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r270", "r272", "r273" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r270", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/CompanyDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://RGIN/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative", "http://RGIN/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses - other (related party of $65,471 and $46,713)" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r258" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r192", "r193", "r194", "r286", "r287", "r288", "r300" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Shares excluded from the calculation of diluted loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SchduleOfIncomePerCommonShareExclusuions1Details" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r60", "r71", "r83", "r96", "r131", "r134", "r138", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r215", "r217", "r222", "r258", "r292", "r293", "r303" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total current and total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r248", "r249", "r258", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "CASH - END OF PERIOD", "periodStartLabel": "CASH - BEGINNING OF PERIOD" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r26", "r56" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r279" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r286", "r287", "r300" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical", "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r40" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r258" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.", "label": "Compensation Expense, Excluding Cost of Good and Service Sold" } } }, "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r54", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation:" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible promissory note - officer" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r61", "r62", "r70", "r98", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r230", "r253", "r254", "r255", "r256", "r257", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r57", "r59", "r156", "r230", "r254", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r16", "r157" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r17", "r294" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.", "label": "Debt Instrument, Issuance Date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r84", "r253", "r301" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative", "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r18", "r98", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r230", "r253", "r254", "r255", "r256", "r257", "r284" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r51", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Net operating loss carry forwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r51", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r41", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "negatedLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (loss) per share:" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r296", "r299" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r210", "r296" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Federal tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r296", "r299" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r296", "r299" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effect of state taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued salaries - officers" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r40", "r79", "r88", "r89", "r90", "r99", "r100", "r101", "r103", "r108", "r110", "r121", "r146", "r185", "r192", "r193", "r194", "r207", "r208", "r220", "r223", "r224", "r225", "r226", "r227", "r228", "r231", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Financial Instruments and Fair Value Measurement:" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancingReceivablesTextBlock": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financing receivable.", "label": "PROMISSORY NOTES PAYABLE" } } }, "localname": "FinancingReceivablesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/PromissoryNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r21", "r64", "r65", "r75", "r93", "r102", "r104", "r105", "r106", "r107", "r114", "r117", "r118", "r221", "r240" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Loss per share basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r21", "r75", "r77", "r93", "r102", "r104", "r105", "r106", "r107", "r114", "r117", "r118", "r119", "r221", "r240", "r242" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Loss per share diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r97", "r199", "r200", "r205", "r209", "r211", "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r87", "r197", "r198", "r200", "r201", "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes:" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r27", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r29" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r29" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses\u00a0\u00a0- other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "auth_ref": [ "r29" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in accrued salaries.", "label": "Accrued salaries - officers" } } }, "localname": "IncreaseDecreaseInAccruedSalaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r29" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "negatedLabel": "Accrued interest on loans and notes payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r67", "r91", "r130", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense related party of $(18,758), $(17,213)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r25", "r169", "r172", "r256", "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/PromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r250", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r63", "r74", "r258", "r285", "r291", "r302" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficiency" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIENCY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r82", "r96", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r216", "r217", "r218", "r222", "r258", "r292", "r303", "r304" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current and total liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r3", "r62", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable [Default Label]", "verboseLabel": "Loans Payable" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loan payable", "verboseLabel": "Loans Payable, Current" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets", "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r122", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "THE COMPANY" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/Company" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r26", "r28", "r31" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r31", "r66", "r76", "r81", "r85", "r86", "r90", "r96", "r102", "r104", "r105", "r106", "r107", "r109", "r110", "r115", "r131", "r133", "r137", "r139", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r221", "r222", "r252", "r292" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows", "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency", "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r104", "r105", "r106", "r107", "r111", "r112", "r116", "r119", "r131", "r133", "r137", "r139", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements:" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Promissory note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r24", "r78" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedTotalLabel": "Total other expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other expenses" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLoansPayable": { "auth_ref": [ "r3", "r62", "r72" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans payable classified as other.", "label": "Loans payable - officer" } } }, "localname": "OtherLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds of loans from officers" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r41", "r73", "r246", "r247", "r258" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r79", "r99", "r100", "r101", "r103", "r108", "r110", "r146", "r192", "r193", "r194", "r207", "r208", "r220", "r243", "r245" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r92", "r96", "r128", "r129", "r132", "r135", "r136", "r140", "r141", "r142", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r222", "r241", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Income per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Value of Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r280", "r281", "r295" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r280", "r281", "r295" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r186", "r187", "r188", "r189", "r190", "r191", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation:" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r20", "r40", "r79", "r88", "r89", "r90", "r99", "r100", "r101", "r103", "r108", "r110", "r121", "r146", "r185", "r192", "r193", "r194", "r207", "r208", "r220", "r223", "r224", "r225", "r226", "r227", "r228", "r231", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency", "http://RGIN/role/LicenseOfRightsDetailsNarrative", "http://RGIN/role/PromissoryNotesPayableDetailsNarrative", "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r121", "r239" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency", "http://RGIN/role/LicenseOfRightsDetailsNarrative", "http://RGIN/role/PromissoryNotesPayableDetailsNarrative", "http://RGIN/role/StockholdersDeficiencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r20", "r40", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ScheduleOfIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r39", "r258", "r285", "r291", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances at September 30, 2021", "periodStartLabel": "Balances at October 1, 2020" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' DEFICIENCY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r52", "r53", "r55", "r79", "r80", "r89", "r99", "r100", "r101", "r103", "r108", "r146", "r185", "r192", "r193", "r194", "r207", "r208", "r220", "r223", "r224", "r228", "r231", "r244", "r245", "r285", "r291", "r302" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total stockholders' deficiency" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r44", "r95", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 DEFICIENCY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/StockholdersDeficiency" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern:" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r19", "r42" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfChangesInStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r19", "r42" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r19", "r42", "r43" ], "calculation": { "http://RGIN/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Less: treasury stock; 4,428,360 shares at par" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://RGIN/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://RGIN/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized loss on investment", "negatedLabel": "Change in unrealized loss on securities" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfCashFlows", "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r36", "r37", "r38", "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates:" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r113", "r119" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r111", "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://RGIN/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196816", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r259": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r261": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r262": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r263": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r264": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r265": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r266": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r267": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r268": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r269": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r271": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r272": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r273": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r274": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r275": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r276": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r277": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r278": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 57 0001662252-23-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001662252-23-000007-xbrl.zip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�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
"QS'0V21J%@T6";T [)3_0X/=#L@)PU3S,TE@8PPV&%D.N.)H!DJ M=O3[L>@9#E-Q*0XTT'3<)88 A;BFU B";W,E$_HW!]HO# W2&'IT5>!1HF-3 MA+[<\&'H<;<\F(PKC_@96 MJH*&+?Q:6+B(Q"+U6M.X00QY=H8'J/$],JT$\.E;0U.ST#."1R'48;A=%B(; M&QY%(M4;?)UJB%=V*W#&@W.(6SR/GDWASTC<4"0J9,;37\)$&2 6Y),#I'\: MG\55=_>_X/Z'D;X, M&>B4B-"WAPQO/3&$D*XPKGLGC@/YS 9?HF:B#SO(@@ME2Q S42I3 >,F?:0 M?H##WBAIU>_UN,D)9JS,1Q0IA8C#"X?MXN(B(Y&G(K@=K0L"'[1/[+5D8$*; M> WW1# '(ZO!KX76$XOU.+>@H,,D/B@A1#P"YQN!EIJ.CA"3*JI*\ZR 26MS"06'@X M46A3V;1^],7 =>7"0 M.S5WW? ME>H&NE'&$)UAX@>65@:76*21"%J1)A$)%KC; M1)!H<"7(IECV(L^*BJ1V$+YC^7S\W@ [ I:'[VJ+K#6X.C)KC6X2O(DD<43Q MDR*2XG"HNHNXMF=[7%T#Z8VF(DI9B,95X*;V2*+T'!05:=4O. --M>FV8C?<0=]G !>628Y<[-LUQ\2 M^])MRG'BN3X\YP6NM>,/25YFA(*O&5Z8>LP4!"N6B#:8:-K),8KN5B YPW'GVM**I$Q1'BYPF38@=D+&.<^S1H8:2:*4AB]^Y0^184A5.$BHUQP' M0Q \-N;ZJ(P38TL0'B)H'&'WD><#@10(!PQTH-PC(K& T$"$SJM75T?>,$V.F\UL9NJ^LW3"8%R8GK%K:B-&H6J*1^XR"R!A](EI\+(@'G,1P74,%GC Z1Z( M+_H>UJ)@,.Z-D,?!E;+OK+?TVPRY*Z4_0.,RC_LUY6;8$#/13*3M\7VA8B9$ M51N$-#X*E@0*,Y)<_)_('6V+5"K!SX++@ ;%7I!*;8Y(X>;E*'0MZA*&UMB+ M769V=SU[%__+H2+ T1SIAW1%%UM0&D;+F@6E!S8N:'<,N08_*>X"F=!M0!Q MF:DG*@0Y3^H$!O:+=2)JKC$8^, =W)&+A1GQ>%(6C'*TVD%U R8$3Z%?3--Q M\CGYCGW40 @D/!9:*",6XJ\A1N:*="<\W0[R!P>YF_*#6?8N,3R4)5Y433H MN5 H*(8"<_I!!7O:8+4FX?8K_/KK-G-CN.7CLYT>R_0U!XUV5!4TD9C-XWST MH$BK%41/O&$^"I.550&*(:. 7"5!&45U2!DXI@%F3B @2"X2L*!DA+14)&@$ M_@Y[.R!Y\81R#9K&@*08U[WPX=EW4Q"PUS M*7PI[7H.!P8<$%@!A:SE@$5-3%,0I6\V6OEWW*W3]AW<-NU0O))6"DM/I-^( M*#'SG?3NP.[IR^H=LE]*/-F$Q[G;MBYJ+M%-$MDNOI)'>E'A==$:P?),I 51 M,1,E $6[!9TW=&T*;&2Y3^2"AVL:N!3AGN#/BW0DP6[XG8K8&B -0]H-,\R MDM Q33* P/_QM]CO@\>,OZ''[,5'&X6(&::1[X_X/]!4!T."! TR$1R&4#_ MA.T/0^H(F R*1N*BFX.I=PDG74I!=$5'5EXY"ID IK8 M 3GH;]&C1"+7H6!T-G##HEF@==!&L75-&/GCVAM9"]FP*L?ANF!8Z!LX*:?J M+Z0@<64 X0$1HI%6@_H4TD5&9 ;YZ#OA#KM@8^%[A# /B 3P3ZZ:Z!%PT\;P MQH\R*RN6=$ THM)!S0BTUZ0M9TB(X,NDK4T.9LZ0R9(G0XSLMM E5:[%J,J MR,SUC)2KV?VTT;W/*4\* M)L/-8-X#-MKS M%PQ0;#2&A']I::LG8E.N-[YI,S2FXD8*\&P<"RHGS. M57P36Q\+73@\AYC2Q45#&/,),ECHA8&_M._8 63T7C=XBVYH;08'*UZ'?3(Z M?AL@EP 0=FZ1D[EH]N$(G@4@R\3]].1AY7);EZD/08T%-EX DI:J2_B(2%$P MA*, Q3POO.2N5I/<7E OP'BTV2%"ZJOAMAN[)GA)M8[B98B(:YQ%. M^9EX!7./:ETX-01106HD0[P"X]YX=J3TD"7$&<5T[D"EL6BKC"A6;WFV0SHR MMJUVNR.9+B_4*UB5^PAN;=,?<-80J# Z QS 0QW2]"G]EQY&6PCH0#=<"L ! M@1_%0VI=N\.[+I F"@0PPVDI\\XIZLZ-9CEC2 MY_"F:::+S%>ZK3 O8\9QS(IZDML=R3YP0G)^2D&=JK ,T-Q"7QX M9(OXZA@#YJY$SB1(LN()\DIY%H@,+BTP((55I)05@TDD&)QESHCSYV'(UF0, MF+3_>SCAGL;CX1GN&@?B;0%WDK[62&I[Q/TLTQUE)LHTXRBR^S&QV&81,Y:: M)8CF3QDI]E!?Q[B@HPU%\B+*24EKZ.N5__88MH# _)J0]N!9?C7)1R,D*M<3 M/-:)6R1<0PF<+.3A-5DF&F'34&6'PY/^FL@F^2%%@ FV3&X1_/4,WJ2%KL%L M HYP"4H^&".(9?&;5B[7(6+I#H85IFD+( M4VTI*:&94$:C$'0"H2V2N7B?19ZHYMA#K'M$KZM,,^&INSC=TXWT7:.:#^&R M19''._(%UE 8- ZBUAF*6K="O8)R2!!BKC+%*B2Y?\GF_J7)?(&8H05O\#0+ MO0*!2_@"Y3PJO&/&,UB<&9.[ERC648.-:9;'U?K& )&G*^>H387>+#BFIT'(#7Z@PSVJ7 -3%@!31,O0*"A8;0FO!=A=L@-S5"V[,[( M$QTWND8;8W6:2[%;),<'&6K5P-8U0 ;'TT:RU-+"\&1T5OI2,KROF(SY2%<* M.3$L):\B5>2;94H*\:%!SC?!%5W,=DM,ED222"9IB+ MD*EUR"N1S^7VE3<7O$O7J7:GJ&INMU)Z&UXN$B B(B # 3$+AP@P>#MW\*&' M#@ODA,6YLIYF6OPS<(J5* N$6S0HI/- :7,_'D.@YT9,E"0 MLB"L[R501JSCI7",R8 )/#S>933,FO=<@9R,%I3K!@$&F2K.,^1)088UD9RD MHCVFW_"VD-A(.YZ0A;EU'UG958.@ICZ0D]BF9"&D M_5!+,D=[R[V,R0Q@N;,OHH*_"98TT1"* Y!:0%_>Z/4)?FH2J9:SO,4.21&= MMGOJ.S57_O,1A1Q-*SP@/!VU MD(W,S\#$)KKC=WT0DJ-=[)9$$I#OEM1#"M*">HO==QWR^]A!F1P?=N*"2M#I M!SWD/ I\=I6/#(Q20^8/1Q8-2L9!UHL(EH&*BL$+2$5_XO1PL !.2X]9[]Q2 M:GX/LST+:H3BNU1.IZ$O5RB+(C^%&BP$S?>I!IS7K_/6KRC&OX]L2C\'12_H MN3B0/1(<:=UKHD,!9ENZH*AS/1UU&;$4B.B)E7B"!"9%;'ACJO&14?FQD5&U M/>72<&^4$TWVN7]U##?(5PIG#7$O[HA7U7MA84.8*)7AP=VP_C)XAFPW^"'B M;Y,I8VX\L+2-!ZXX'EC:Q@.W\< -CP?&Q4UA3-P<[2GD(K)--)- Z^DBCKF5 M3^.!MK)G?60/'*81H,A(JTYZ4=(IQDDGOR>="$LV)UZ&4L[)127FP"OLGG5\ MT>NHBVE?O 67S5N5:%Y&S2F?L *N#HJNEU5.#0^[LYYHE/EY]K>2VR_FB[Q< MJL\T_;R&<> M^J2R2N?CEPO1_P9#MN12%_-N9.MA88.&Q\8-7>!!7X+VOU>B$]*IUL9Q\[9( MJ.0YR@$YIE3VWK0E.^:>0,\Z]8P33' #MW[E,YY MXIM ZLC]+&!++9FO0-QPJDME5@&@3G2O'VWS!0*,^(M6Y%%MEBN[@2M MQY%!]N8YB-8="1/WIQR_/R#NOF"7"Q%L/S9<+-7$U@.;=8MV#L_>U=:K'\TB MWH+RUENP8F]!>>LMV'H+4O$6+%L5"*B\'0\PTC,ZZ]B\"^B!XH-*YF [O9W# MB]KEE=)L!A'/51M\JPN4QZ7:?ERJE4"J\00D#!Y?D@:/>;5!N@1Z3T 5:OP& M!6I$.8F7S"0#KP7$>2.&GX#&[LE*V":6,3G*A>]TL$DVF7[\YP!TQW>,UVEA M Z8%)INA:V7&-I>>4O["(?VP4+[#2J$\[DB+Z]^^S=.Q=-%MPQT-VK8I M)YA=?FR>B4%ELJ;X_*I^=(3CE!TMVH\W&!#FAC;W$W M?D1BEV UB-;5U!F4#WFE/''\O1;VM\4TEJ!OO!@J09EILL](QK9DC;>H51"0 MAL,A7)O[)501O[%[L\[3+6 M/TB+-JJ7Z7*^)2O],;,!._Y@]D( N1QL'?A\OL!2MAQ\+SN'R<1%B2BQ$;KW ML;'BLD>OT8FTVA7L*YC/+. )&U]P)=/M\_Q<>"F-?).7FYI"8S,R0P\)GQ^/ M'?#(#'^):"R.Z5[8^I 2)UW)",+R9CP5[%?H4YY'I)6O[$<],%R3\<.*, I* M5);3&*C]L\X\3(RU@KDDF1#")?O*5B*7T7LYXOK*Z],[T/7=:M1YW8=N#Y&R M'=^4:?W\UH($:CLV\&]0A^'N8PXP9OET9/T M"4SB(O(778:053.NYD4NIBA\$;P"KQ31(.]GC*FN?Y3V1+$?L MA2]FWEHRY2;RI!RQ2,)!"B9^C\]JK>/:5R&.@I(BT=]=M,?(<,BHD0LUGHA? M*-P$\)"AK!T8PP_=P"@WBDS[%/I), (2<\@)$AZTB*"6GUHF3.^.G1@"CCY( M&F0; 8!W\(HLD^7M?:AP*=*'E,J0L*$A=;[GGJN@)7NL\2YV8P&"XOR:#^\5 MG21#X45W M)R"Z](N?.>'D6)R9H./C ML:Z4B)+@A^/4H"F@S)J:A(.(0;PS4%3&)QZ1IAL2##JHWU,!5V1_;<=@71RK M0V/3+6S@C4&OS-B^-;%3@>:L*&8/,6%P91%) MT1B"08X9B.)"P8+LK<*;$,;K_E!(!5-Q0RK.!%1,R_-3YJF0M!&AKHSQL?>\ M9JX;@9U.CI]7]/9KO%^?O.?X113))EQK'UMW9KS1$/'XP.0,8E@@*THG:!R+0T'^FID3HP[B5@BIE\*SA?A5R+KD32MT3S>%;VB M=-.0_TA")A8QKCYY<38:C@BGDE#+U28YA)2"O'>6RRN)0,]R.4R\/5@ YOM@ M1+B@8[SEW.#!H404!2722+AOU!(T&S("TE =XBL1&@.FC\?/6U_R0K*A)W1& M ZA%CTQGB7!3+G?XIHF:X2:*[IPT6JE#\_9W$B0 W%:N^LD2:6,&?ER27(VVLJ=K>L'F'TYGT3)8L'?P=CFQB]VPP M]&2A$V9MT]+92E18$O\&#EN^4>O(VGG9ZHK$)OX*AV)T,]J$:A%0'5ITP3HX]9I7 MM;D)BA2H7K>\5"SDTUDQZBVH -4I9QJ+MX:\+ENNGN'[Y4W+@M>_,D*]H@E_ M$3S'- NTEGGS,E!8.-LE92SL)4A9_K+:U!YST\4L$1G.%[$F MT3@7"?*9B&=A@\W'N9')_6UD^K]1' MQ8L2CT%?X$E:ZEA-HEHJ9(N50C97R@G-.A-F\86Q(VJ0*"P!WR//!DT'(%45 MS"E5S<>FG'+9U[%Q;AC9$B+#"[^F: %7XM&R\QQL,FH!HWGE9=,?C,-C["C) M+-U==M;UB^Z5QS)X.$F172.DQPY)*UH4".:\[0Q%G@"FMK5'Z).1RCZVZ\#6 M.UQUUUG'Y!/[=(E)[LP3!7^7[-9P>?F!Z#(9#!S7*6#0-]K&S.6PUP#V(Z!6 M"3T^%$&H<]) C/8_"9SZ_.<'&\H\^/_#11=Y^VYN+T_O5\6-G?:_=RQS%YUQ M%41N-#[74&=MSQ5N&@PV=;#]JNX'453?Y=U7?8?'3]K8#9FYU +Y!;>=G[-M M&E5(\Q:QM0>.")%AH<#YSIU\_D"&N/CCIL&-*/31#4V?NZ_X)''1_%LNQ*>F M1)LY1[RITDDB>''FKB^:L<-UXEU4T:85#PMTJ-GT2S(+%QNRT$J,[:5B!!+ M9IQ8D"+028T$LW1GS2J./HRMB=RO!]$."K,3*<;%4\Y$7F,]&BJX :[R0F* M/#X3:15'4B#H]A>+;;7!D I29P(,H(AQ,QQ#(KXA$KRZ<8M,I.<(*J/1PSS: MC7.)15[:D&O=VI3&-*OR#8:>EJAG9=SS\L3TR%WTFAQ0C]# %[-?^O.],L-E M(WY)&A#_Z0XZ.F;X:KCK:$>X0T+?BGB)]"RUQ]V-B7ZWF6F;F#2#:D9=\UC/ M=D1?+9$GY^D3$ @4!B"HP[A/)W@>MH^K_+53&/=JI0O]61BI"U@! 1$5 )Q@ M8\0:NA4$X6:5#VWG'=] P%HI9D*:Z\LA!K:YE SZ[PPWQO1=3//6 AZ_E=)/N!2:]B#DQ(:W'!V9R$X*N#95+K^ LN/01 M&663TBEV+N0R7H1WOJ=AL#T'QW4@4[:= ^4_]7JC4:]/LE7!Q_.5/^G/_S.9GI[R5%Y-=KW/WEINQ5!N][*TO3SKEH :Z+'P MCCSY0J"Y.>M2C.7D1S8W"Y7SF.F3?_J$DU'5[/Z^FBT4BXONXCD[FPW+'[-] MA+-H*'6\Y/9R^514I2<^OTXT,O/VSMO8'<75RAOS@-(G^A M.S;O\LPZI-3(?V%@T\1?(OTETIB(PV^D#_#<"F/.:HD:@^1$LIV-(QRQ\[CA M,.I,&0@EZBT3=&,5A7[X2_P71BUN&7F(E#?XH"@DQ ]D'2&/!=(C@<]%IMWU MT+P0145&L!SWI4@[AX;E_O9A,UT#P!G[DO^)P&)2(&_?189*5HFVQN?9M/QA MWS+P:S$SFYQ?;N@:C7Y,3\IQ.4&;X*QLK>-F,Q%\40-URZ5I*;A^F!*]V,[& MOYP$/VC* B:[Q;H &^$VDXQ;:9R$ T\*V5(QGRU7*A'WU42FVT8D7 ,E_ZU9 M/J;)EXF.N?\^4*3&]U^IE++E_7Q&.M\P"QNG 8A(<1>Q,*"+$90C)%T)CX]N MC]K_F%KZ1VZOG$?"X7@5[;?$JS#5%(MO>/D)-HSA\PDRO(Z-CTZX'V(JK1VY MGY@- OLJX7P$Y8N&R1QRHY2U2+G_ E3Y*O)P:P/NS,9D7/1X\BJ#P8#FD# " M!VB2EI4ORZC1+D$Q)-)J&(N3HX5^!*PDBN4HF@Y3]@?_?@( M<9V!@Q:@BPV.[P\6'<^94;/A]/5IOX_ 3*68LF*E1V-K; M9)%%Q&2JX.F>B$D%S>L<^BU?%#,49,TN")^!89KX<9@>%7/$PU5%^HO<2DXH M=SS16ERX^!;SJFS!QM](X- O LIJR[(\BHR?C6ST_-*)87$Z MJ<8;7^UCXRL+. IJ8D&W*^SJZ/,Y8WA5:Y9FCER#U*V0@(#Q<;51X>VPT 3F MB?S4,@@5[PW.'IF.SQ/;@8NO[Y[:]@T28$O6V+W"[=9%KXF@CM"-]:@ S1RG MP< 5PNEV.-PONJT1K?]$NE_G%/& "KZ69 ME3@],BN-9\[2>(X':3 ;M+#"YCT#80-2D@//XN$&;>3=F#^*0VAU/FA3 M>+.ZXJ!-<=#A#V0O+K1S9'<'IEG"HX5_7CC&+3R=B61@G0;M8>&R()84,9E4 MK59+>"+!G1;*Z7(IC3]E5 MM-D41KF1TKB+2G3ON ,ES)78$0UXW*Q$AOA8!,+ MA30S]H6!"I<^\3%V[/-8;S0!$-#/^&<#;30.";9C&G^,4KPG/N1]FQ(_EGW/ M$K\TC1N\+9Q*@R>HRX4[RBT<*=!PX5IY\:3>3KH:PH/ M"T=T[H(%W.:#7V]IH"-W$\Y82G2!( L_2LC*XH1,A4(PASR)?[MC4_X6ZF&CD!TYD3WYGH(]/!IHF.)QT(E=R@YF"$3&I?HA^0F%'+.$L&NX%5Y(E[4)OPN>]4ARZ.J4+B[ M/A-UF"%VRGSXO/(&64A&A&I)PK0Q!L%16(J'6!FH0E5)8_RCDU MJ^Y7)9EE:/3XM-JCK.AW!%_R^NLI:Q9*V4JY&)#NK#55KC=,KI316<=AI 49 M%B=N.M8P:,;GM MX-%=42+A+*Y>=6H"P@-OWL3#$"A#F^XR+Z))-KP"!G,]W MC"_4MDU]Y_ \.*"&.*"Y&=$3JR1'#R;);-SOG #.@DG93P5!?7YBEM-KO\GG MBME\H9*%_[Z=FH]<&@^KX-&_5\;SMTH8!/C(53WNS-*QQ2MIRZ!3SLX;30H/ M_#'%O9^?XMX7MWK*KY+?,3..D%\PZ385X,N%['ZQ^F3@GT,)W^.IMDE)7C.. MG%J(*$?$"*-E;7,3QZ8@*@$Y0*&Y2F'6@TFGN6@"VR/@*&;W"Y7'P3&>U_8" MX9:E-]V/BG&+B0YT&2$H2>+R$UQ(X.:IA64@-T'_"9948DO288#IC MP3Q.<.(.GDQ7,YRP_V$-4*Y9GN_*U([N$UK(STXG5;.5?&ERZYFDK:L+;1U0 MKA8>OW5ERM8SP=;_ $ WIR^^:** 6$#:Y)@@O;*:S9?SBY-Y)JZN:I&E]G/9 M"<&[P5P>%I'N_V(5NU1%.=9&^G+C;@G'>H= Q_ ME*OY;%XMQYC8&*GL%]4LFGP+FB#1(\^D8E)8ZO*"9K24"/H MJMC17,KX_T,M9DME4I$S82MH+O>J^5*6"SWJ_16DA?.68?3C4K98+7"U-?Y0 MM%'8E.X>*L\0^Z.4+:OY;+E0H+ - )?1,*A.L1<1N**6_QV#8BWP?*FZGU6+ MN=6W#7F9?)/072;Z,B-2?9=)G?:/_'XV7U5I6@L>ZT+:SYY,6HHO&\PF^0-T MR5PNMYA^'!3\<*,$4R0P!P;=XT,^45KXT4T; [/T3UDW],H.2[9L$UU$;C4' MI]DA&@;P$49I+=M#&^V6#[7+A,T#25/'L6PN:H<8YXOV\,((G4.3\.QPDES7 M%WTP8M%HKH-&RV*H%F4, @W'8S!/HT'8L/H9?*J<2 TU#!U&0[(=D5@8)##4 M+,LGCHJ9AWOHGD*M'+_I!N2%TX?:."2DS\QAUS>E@NOVX3<9*DZ!EPZPR6H\ M:!E&;=UPTC2MY#)&_$$8M*#.T$[#=\*"B)OQ,+W$.JK[.'2"C+1T,U#33Q3^ M:...ZCQ$O&G9J>>Q$XW04GB8P8 ARD+!8^&M))D22Q_B0?>>S?-;"1E!SH:% M[@P<9>4*\PK >-"",3A<8E%2D8;-*,.ZE:B<$F1I851>-O7,1)IZ"OET&_&@ M=?R!S_,PR,SC4S\P,I@5.3944X5/ SGRL+]X3HZJX2/PY.B$>/ ? <;W90A- M.L.9ZO2@%5[\D+:]OF/[O?Y$O1]@A[12U"6QGRFO[!093'+:W\1T+IG@$::= M9!P-43[)#;VSR84>S MX%RP R\.K_ XT_., 1/S*V2JB"3C2'=9K=,78_JH'B_(X>1\._&V\/Z> 7XP M3T73\9+AUQ,C8K"Q-8H0<1PDG4&RN#0M26Z2=[_FUPY8+^_B&J96B3^3?QN] M-G19!VAG9*CO*^C5+OH51;(.C26,#$6<11CKE6,RW:RH(_&@:*Z%N5$7-E#> MJYQ>W(R6JN9RHNH6AU9AS0 OZ>5)@S3!2HZ)=C,F_ N?-1QE8,,_1=YG1V(O MFEF&V&-!#K'@CB&?F)9]SZ\,P@)(00(-8!E_6V;\;:/@9>@;9T*6P!\T>,Y M][BG64%7;?S3T4;"9R[A4/B<'2J\I[$YDS-,L?4R:50X(BA(&!9LFNJ3*4,,1=M S.8. MOKF(5?>PY04&YZZT>UAHE^YA790=!2YM/M6/ M(ED>/8?IAG0F)$-Y)"6\ESW?X%^9V48,Z5 M! !E6\_"<7LZ-A3'XFQX?]PK8>E2,0SRHSTQ_A:O $YHBTXW3!#+H ,X#ME" M46E)%??P,ES5C:N?F0@ 607UO!X8RQI5;.!/*"N7,F1Y#F M\%*LA0#VU&:<[]-"/*^Y#]]@ (R(<, T' '&YZF)B!D+G#E)M!Q="TDUN@)) M/#R$H>V*MX%L08=$C +;3'P>W&.T2=KCA[)(S.9;+*^A?>JEYP2P0+P_6UQ*6BE32\KFSE!YJ M\WP)+H:050'#AI4X4X9%<,9T)F(IFV03 Y&#%62X?3X$'JL&@H(^KDL@@^R2 M+8PO$N46J'*&9CXY(##HC5) SX:;X^I;9"CN!JL7\\/":FX;%UYQ7%C-;0/# MV\#PZP@,\\$PP)9%\XVH(\>Q+1O5MZ!\_:4;<+Q3ZVB-2@CH$&6J)C5/@\A%:PR2)OK"F%FAMK2E'; M4[[ZJ$Z(PT"-X2LV3!1_'P<*L9NID:_G"Y_C?6FX+S WQ%.I*TXA6U+1_N(?V-/OH4^]TL?7!-$U:^QS-,W-MEY !K?'JC4D'N<,GK MH_&06[L_TBCH2IQ5M*01,C']8JH>,J\V"Y2-G83:IOQ.J&'Q:A%1[T4=GB=K M2!9H^PRD^>VL]NVX>=4X3CRH@_&I* N4P\3!?RS( 1(+R^K1Q@!'FDD.DU:?,6_Z0"1.;:C\)9*Z8%))0YSQY^IR0/OUM#I!:>A53V-*02 4:2ZD6@"KW+&.>T.J-7 MA^?$AO&+XKG3?0;QUC%O[P0KCE\=4DN)[>1#O%$RVKQESBAC#61_#(=)\F4J M!I;0K%XZ4Y9D&@2^FB4O/,O+IFZ];*OVLJE;+]O6R[8$+]ORV4E@DY+RRQGQ M9>-CXZQ9;YYEE>99?4^IG1TKK6]'K>9QLW;YGS>,:VB%'M=/: M6;VAM#XU&E>MI;WS36#YO%VV1$AP*2QVU_!T[O7[ZT*N=JVJZO5PF!OFKA_V M!X7?.7;[?7A1W<&I[_#^$3UX$%$(=Y496%U5=Y)RNMU)9(,-I@O&\KC6(!*= MQ>K^->I?N6H!L'G:\ M4 ^/*J?"8?UCJ3^Z-_=N056?<%@+MCH!7O_M\K)Q=J5LCW#Q(VQ$CA"-3QS* M>*N9J.74O+I(:_L'NT# 6>:;UP.M_C 8=:\?ZE]_?Q]\J9<_?LZG>@''-*ER M\<^XFW7R?Q'L])K]J*4IDS:-^P/+MDX<43-B@;K^UX[ W<%LU.WPRI1[[Q*5 MRII[WD7FMYNK[A9 %//@PU\[QKUW8/D#W?9TUC$&&C V\0^7J\> 64;_PA%< MM-2WUO'.(55N5C^\BP,XS4A8DYY**T-S+C4T9RNE%+$\3>AU?!?N#%Q&:F=! MCC>,4<.60:T;NX/_F".M>/+U3CU_RAU\= NI!)UBZIV,SAV*MH])I*#':!6S MZ/4QZ\RDM\N/S;.#Q!-8[E6NYDMS*2SA-!;'T#/GH6[3 MR <*$XH5:E)7ZB[ <\ 7IU@"EJH43;:0E'KD*@L)+WZ02]8%J!'#H^F4=O9T+A*CA==S M*JDQCV*VG)NO.CSI4.;:9:=A;4;-TJ.!/#Y_/695&[]'%]^O2N?>@[Y,0^VT M63MJGC:OFHT6]P->G=<_?SH_/6Y]95[:V=*Z-M:\+L4.KG/X=R)JEBQE$'VXQ?$\9D^R?ZDQ7Q:?_B>SU\_?/Z>;Y;V?UM'7KI^XV?<&P0\ M[-FZ*Q*NWU O!RS^T1P^O.6/,*Z&"*CF3D)OP=3]7_)5+F 1^/#::%YW,&S M/?S%7R.]N]\Z[NKEF?;6@JLG$E(^+4(J@VJ[KTX0$C\ 'F-$ V$"2\=/QI*( MXMSTM>K?YU_S-U^-I6$I-=94+&.[WX3K1@AZF[:TF\MODC&R7!SD2\5LJ3K? MD_)"&D*:.$O/OU$H9BO5I?#IJ'[:& Q->\28N!+S^77M+ M,6E7PTIOSJ1%U[K5$L=<]"V9N5"'QEQND@MOQ-5Z&O92] +D"FH*V$N\9+G( M):,DR4138?_'0+]J:Y_\W%-N4_K:ST6\%^$CC8>4R"(!74LV'_9+V%)S,R_1 MHMA*+^Z6"K;FYIC4P^YX4^]/*)9R'XV;>_VLRVOU1,0E]H-2P=Q?JM?%8_.KDLOU VR *\85FY()'F@YM%RJOV MW@3S-;:L)LWS2=$_5"WGL\7*_LK8350[GY490ID#_1>:(U#0O!X:PUPT&MJZ\/2ZZO9J^WJTAI$O M77K:TB*$6-#.'BIZJ_SCG,T,( MQ&FK"1+)?^O5C?N24_B?ML@)C*^VM-C[XD2Q$$AI:#,2I%*VE)MFD<\D!<6E M%613.X#U/6=:8X=8GG*(O%?@&#G4?OZ3+]C#7J/=FR2'W$(K"5(P2S]/[VY/ MKQX^E1;'.U]I;;*1_VK<5],9Z=*+Q2XB M>-LLG]]3D):29IXBTA)UMJ-8%"JH;$E2U0:?[PN]=JUVRI[B*$\M[!36=B4H M8:7D[8"*<.Y0#P&==G;!',)KDB9VYVD5NU=MFC\3-+'R,]87#'9THU?_]Y-A M*'Q^7&;N&UY4*WLNG&NIG+V?D,1J\J'/T= NRP]W?_\\.7L8=!:FHSEJVJ^\ MZMUT&R/6OGG$D:R)MO94R-*4V'FNLCU#;2-:B:AN$\12F'6RB;K;7=.QAH72 MF7Y?F2241RPGB.1!:W[[^+%1KH_,1Q_%B^IQ3X$J3>)02_O9JJIFB^JS5+I' MG>!YJ/^-487/OK/CG_8/?=^@N/3>C]\72819 57IQ_510-;^2 M6^>#X#3S0C/TIB7&T(_I^/N__E8+U=;?-Y]+:^&.#:$&!F&+F9\UKW0@OF%[0^A_+7X]^%:HO6E(@(:5Y4@!JVI3Q9C9IS,?=TEL5 M5$O5;&6!MAJ32'B[Y%NU'-RE*+"RA7PN6ZI4GHZ[N>W KAR:_#>*>Z/$97+% M93++/;O^_:@VJK?7/?7DE+GN@>*)77'_U:3Q>#0- US]'#,1VE^&H_]]^3&X M.$\P'*N++24L@_NFX?YHWNY_/IIK&20L]L(&P:(0I6D'%+/%/$B9\M.L !D" M\M#MM&Z)*7/8S^3-7';=%V ZK:R4MPO\;ET3AM(YEQ0SAM(_E[EB83)1J&EU M3!]?<8%SEVRK)N;,8GKFE7UF6X@#QS9->*0IAKQ&^EFA')$YC0\?K_+_NS/5 M^U)[W5K:I9._Z$:P]U^A^>$,C0VC]'2((&VNA5/C_MK9G4Q\+%7WLVHQM?YM MKYB%+?%@G\'VIAQL$2R(_6QE?R4\,/^(IEH1[D9?M"]W]^^?5]-BMV+ MMNN+)&23-_[Y+&\M&L7-._-M8[]7<%Z;U/)/#C+:K-D@2YT&&HX<8,KBHZ+V M%IA_E'^OG ]IJMP!0M5BG.2V0Y&>/A3I9/=)8Y&V4Y&V4Y%6.!5I[.3FCCRB MV94+C3RB22BQ23JM*_C/E\;954LY/U'.+QJ7M:LF// TF")CB)ZV@#R7)XT5 MREVK:D&.%;KX=7=U=/S-=GYT%AXK- T9&S9@*%%Y2AZ^4Z;A.W"-U>O($"$_ MU]EWA\W;QF5[G!D\:@S/3Z8Y2@/'2'(PD/SB@R/IH^A0H4? G@>(U6H NQ@A M5#+OO]]?[1_=?.RG!'LX/R@9]EDCAN&\[9D[-%Y$S M5/*@$@D^%S4#-ZR4=*6(*RT9<7.SR\5H9*O7$-U&8\V_NS\T5>O=JOV?2VVU M%P 1]#Q=AVK*C2CM# [R([, B2;8M35]8%@&GJ)GW#)QKNA^(I=ZU[>N'[[V MO_CM5LGOCI[2J^HQDYHF"331TSX^0%C-#^]W#L6>R&6DQ7;UI+O^A'%'BR[Y MI-%%P!>2/4W"XPCA3]2.6RJ E91*FC_SO5KM^:/;Z#[^^?+G[ M7UE;>;B//-:*O9@X6MLN%1-X7C=.LN8:X#H=TTNR@^?Q@)7D*8>:HVF[KL+= M<*)=_K)TR3WNRW(<&[$QV<5<3OJ>\=L#Q4*^ M9FXC,QL&/$L MS<"W)5(_!U>VU;G\\5NMJ_.8_XRU$Z6URL6 9ZY8P/HGHRB,0/>$ '?XZ^OXSSQK%GIXVHI>@%JG[V?ST 1RI8#D\LI4FO8\A M=WD(G9+M4RAG\PD$O :2^=EX2T?QFX:WXI21,,_1(Z*MX[Y9#H,?/C#]HV98 MIZ";G5M-ZQ:V3.%U%$MGLFA@O_CC^N'V:_.+H?[SS^C34_I5/L?J2Y8^];YF M]9AB6( YN16N8V*?"];QG;5L+SF'[N8&SBS= MC3>SJVMN'T0@2L 'R[@\]W]\._KXXREUZJE)OK&VNXHN(=\P!CL#XZL2AJ5\ MMEI*S17_BH7A(\]J&:(1. "HJ:L0CNE4/])./]:>4G__9%-:%(9(F:IHD:(PS+GO1'I$"H#7KGSD,1)H_E&L7K17 M\]F\6DZOQF0N/UGO:J#E'^=258[](LX&??SLAWG'.;&-SWM:Z7QU>^L)&U6$!_"J0!DO'\#K QP;1HI M/A+CJ7*6_%Q2C#5RW7*7E1WID[G+2Q_I F'J!9!S;)B^!WI>E,<4"NSBE_OI MPAL5TE-N%F,L.@?G5=)A%-5;YO(O.=37Q5ZB\8/OE(+"]!JP!BP3];$HZ+P[ MT9B66TQ#0[]^N#K__*WV\_;H^/=R^C%,(3\)J:)Q4!6+8,7D%-&.*M*;-FW= MYA&V^S,K[Q]U(*DR(.I/_\B&P4^DSA=MH+!!9_EDOO-"9SFW_]44C$3Y;ZS_ M-S&<3_=W?M/HGY=OG\)P'J?)/([+I*[HO#AM3CN)+:=Y[:>YJ;PFZ.2RM(8& MF]0B)M9V8!-ZPQ2V;6!6W@8FOVT#LVT#L\YM8-BB;6">]*(9G5+JGVIG'QLM M>)0<$/QBK65*UZI:E*UE[OXI_GAX:&K>Q_TGMI:9@K (OM)I M.2/(OX+D/^,:/[_E3&*!3MLVPP+G?/7/F:JB!'6AI]0I3P7FTU'^.M(]6)P) M;\)7MP=#VT*V4;LWW/"Q>-S_"_5YN7XPJOLYM?F/;3EA)X-40%W.MLN/WG8D M&"GWG"^I]JE6MGZ4*^GN.81S_]%P3ADK(F'^VJW7OGE?[_XNA)5GDPPAO!&S M]S$A*B*E_^EO;7RT@]R3J?_8O\C=_K!_:"GL:>$-'#UZ [$FY!+ZZE&]6_"^ M?,J;*=^<$-(JX*@PL+22VV_=S7G)AT5+AQ=@:HEPK>*S&?YPP96P)9TPYXF_4MTM^#]5C+>/ZOKPT7V_H-O7I]80N,=Q8 M*"0V0I@U@N?:P"D31O%WIWEY__L72S6KX?!(,S6KPZ=EG7<\&Z.):E8)VJU. M6 /52C3#-&$F580JU(I39FUOCS2_N,Y6'T$AA\UTR$-%,^H%P$\S\;Q M3/-YI1$(CDM6)Y6E]2I[L M1DR9<(JO@7 VLE/-#-%7.'J"GZQQ_>!;Q8OJ\..)=:,OST\6'T\43%5:+"E[ M=A[UD91.82F8W&C7 MR4K(.QT#=>5*G%H" [::K224RSQ3CULM_UC^46RJ\V5IAY,JFE-$92E;JNYG MU>(TBIZAETY,PYP;O]TO[Q]_'IU=_#I/81C2C*#M(\7\2RN:FZ$PJ-7UUR/7 M2$W!*(V6LE;&QUN JW+U^&*V7*QFJU6)AL+ONKXV 2F-U5% M6Y?XF$1HJDC+5_:S^?UII)D<'SN9'A^K^NS\H??PN]BJI.L(_+>&RN#8MZ&R M)+2L3>!I88@+ZP+Q"XB,)S2?7V&H;$IO^O4(E>5S$U/N-Y%P-G(ZP2R71.D) M+HG&]<-1N?7UYNC4/^D_90;!+)?$1'Q,7?SDM_&QU9G :YT^O8V/K0U9;)9G M9)WB8Z\JM7B#XF.;F7N\!OQC^4>QJW9DT( ME];F;%9WP^*VN^'*NQL6MMT-M]T-)[L;/K8)8:?[8DT(:ZU/RLGI^??6^O0: M?%R#P;QL,/CY]S\]XTO^J$/#RI_48#! 1CJ-!.??DC(287J-!"=OSX(!J,0> MTH%3JEJY3DC??JCWG?O+UFWYVUEWG#$L-&)0DL!/ICD$W*+_U[!TIG]H.^\. MQ[Q3]-FCE@KRO1^!F)20JEXG./H>ON>\[_<_1R>=??9LI,Y#5.#,6W@#B\Q% MQ.&/%XZ-@R'UH]$WEX%I+":@6+T:*)VW8#4SM]9V/=1!KXVCZP??_C72.U\_ M?_YG.7,^)G<5WG7EY/+\BW)^T;BL737//BJU^E7SG^95L]%:[(3?S1F@FRR% MEDIDZ0*3>.CJU&BM =\-M/I#MS^\?AA5/AZ?.MIM_I.1WCP%R3S'=;DHZ-/^ M=V;$-^BAN- ,(?ET*5F1V,@JGFE[3,3(Q#0GV;5VP4Z5ZX#EM1A/O0B6Y]84 MU_1?ONN1'7IE7S+8:L_V%/8\^Q+_ M?_;>=+EM9%D7_8^G0'AUGVU'4%H<-73O[0B*HFS9DBA+\M1_%" !DK! @,8@ MB7KZDT,54"#!21PT-.^-LW:; E!565E9.7ZI+!7MM>(.1_>7_0/[XO/OC%[O+D_[SL,NY_DY4PTX#TL..%+'LO)LNI*41=5^/S M0FZO.+V7]A-Q\](IN(IVY N3;^KY W&.3E+KT.+_>PS+!)4?%GIN#-" !I&/ MA_#LVK031>R^]K-VYI5__[ZJ/ L1/E:TMUI^1/*:UX2'TO$,-] -U]1=9WKY:]9R+YV-:ZTDRM61GWZ+^+ /I:@*]782N7<;J&TBB-]9N^S%'>L5W:ZUKN!V.Z2AZ M%ZV+3K*3K.PY:#W/7P4[FL@_(#81-#D01P=81PA2A8. ;4K)A?"Y$7Z/+KW[ MPM'.L[X0IEX7M.[G>Z(O^^?U]X;=9^=1Z?O?!;%J?==^WW, *U+]MZ1Y>CLMFP.F]O*>2?^WJ M7F$G5ZD\AO/>/=YYW]L/^=G14 M>LRIG?\>_EL?;H%:Z*_X5 =BX3H]'?.=Q5A7;NFZ MKO3*7F$\2+A"@8PM?GS'XL)C^A6_V&U;B<*PE\_M[X_)XUULVZ:ZBV:/R'+D M+F2YA/+IZ'YP_= ^V7O(>S9 !D$43DR(Y-^Z@FW*'UB_=8*OW[_>'[I M[$:/ 7-;FOT=J[I]L0Z].=#;<@W/6-U]E*:4L3D;,?/JMN\5")JB(FB0$OC_ ML'#O%F8' O?" FW6;H'$Q3]473/]@_+D.56PC7HD6DZ$$ZW?MRA@>@'2N]YN M6Z@@L[ B(?7EL/?Y9Z'1_KQ36*5K_ZQ^A54G%_7J95V'_Z**B/5ZB==+Y+7E M515SN_GI_I]G&8M[^AU9A1PI[Z\DRV-_2%X07NSMB=TU=P;WN^7F2E2,S.N& M+-TM_:#^X?CL# W< M3_I()F;!F&**.;^RV %=WNU9SE5VIF/=';N\(IA%RL4<7MT>G+<+M:B\W%[;XW4$=7:Z:05W M>YU^Y92\F"E%EMP]L *".9$)[\]/TLP(*+FS,PPHJ2[VWRVL9R7A[LI).$O> MH=>SKHQ[*\#3Q4>JLK]W^=O_W3OXO!XINO33%>)Z7BY?[&^.UH(DW!WI#;NR MHQ5#:"T+1&NV=Q\'534)4:JR091:.Z)4>8,HM4&4&D646AZ07%/!G:)RRIFA MIYKO5P=OUWQ_UKBJ7^I7#?WJ8ST-TB1R=*HG"ES3DF9#(\O]B;_(1NU9U(.G M6UD1@@+[HT,/X8.D16V!J=Q'7<:/0$D:BJ,9(9B C;;($ /A#"/W8PUL+U]3 M ]HC#U\_%+_4:M\:.[W+STD Z+'K14KK57U+3QB!)E&L7S_L]+H?FNV][D?7 MAB- .W%Z7CW[&4/$+XGLV1?=POR$L!!V>_"W+C3/_Y3H_QM2$T8UU#LV^BZL MCN7:()IR&JC!V_K;-_$O;][ER&=B^;K13/U%#Y4(,'E5D\*A*YT?'K.W^/ONR&WN(YF5CU3&$ZD,/WNN:QF!@ M&;[E2L:&J?XUVTQ1,1'04]H. L@GV8EB:N]CYN+_,]-6;>L-5_\4P684]O&K MA7R.*%WS>O#Z0(=9(OB5;H[35X2-M_2V[;@%?%VOXGT)M18+M6$&A]!YF15$?3@N&]/E7I@BD(6X2J(]RX MNJ'W/;P*X9\P/\=N6X%!%[>D,,&L%5VF[H>^9$4\126H'061M62Z< M6LORL2CD!LY&$#7AP(814$0C()<@!-6#OO [,K@F"%_O6H83=@=Z-^HA;^"K M:-5%@25/& +'$M(#/MZ,?!=D1:OK>[!Q^AWR#Y<=&_HM9OZ' WP,%@VCMV 6 M?L?R!UH?DZI,]-5MQRSYO 34BJ>U:KD$0S>.>A?- <9<$[H%L+[HZ5Z*]JQMR*( MO16:31DC?#,8LN8?R!+?S23=\;*_ZWIX.X&"AI<,W"^V:1O^ ,P9QZ&B"7%0 MV>&^)6:A-^.6-_"=T#?<@$-:@=XUX!)M6I:K6XX-=RM. 0M!AFDV>CM MR$
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end